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1 
ABSTRACT 
 
Tumor cells exhibit profound bioenergetic changes with respect to the original non-transformed cell 
types. One of the main driving mechanism leading to such a metabolic alteration is triggered by 
hypoxia. Hypoxia is experienced by cancer cells during tumor progression and leads to a significant 
enhancement of glycolysis in order to sustain tumor growth and survival. The transcription factor 
hypoxia-inducible factor-1 (HIF1) is the master regulator of cell adaptation to low oxygen condition, 
and thus of tumor progression. Our group described the lack of HIF1α in low-proliferative oncocytic 
tumors, which are characterized by the loss of the mitochondrial respiratory Complex I (CI). Hence, 
we hypothesized that severe CI dysfunctions prevent HIF1α stabilization and impair tumor adaptation 
to low oxygen levels. Using the zing finger nucleases technology, we generated NDUFS3-deficient 
cancer cells that display acute CI deficiency. Engineered CI-defective cancer cells showed a lack of 
HIF1α stabilization in hypoxic condition, likely due to higher intracellular oxygen concentration and 
increased levels of the metabolite α-ketoglutarate, which both foster HIF1α proteasomal degradation. 
In vivo experiments showed that the lack of CI was associated to an impairment in the growth of the 
xenografts, together with the lack of HIF1 activation and a significant reduction of the expression of 
HIF1-responsive genes involved in the glycolytic machinery and tumor vascularization. Further 
analysis showed that CI-deficient xenografts may have developed a tailored structure to compensate 
the metabolic restriction caused by the lack of CI and HIF1α. Using a Tet-Off expression system, we 
thus generated NDUFS3-knock out inducible clones, allowing us to target CI during xenografts 
growth. Removing NDUFS3 from xenografts have successfully recapitulated key oncocytic features. 
CI loss induced HIF1α destabilization, the accumulation of defective mitochondria and xenografts 
growth arrest. Overall, these data showed that cancer cells are unable to sustain proliferation when 
functional CI is lost during tumor progression.  
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ABBREVIATIONS 
ACO2: aconitase 
Ala: Alanine 
AMPK: AMP activated kinase 
Arg: Arginine 
Asn: Asparagine 
Asp: Asparate 
ATP: adenosine triphosphate 
bHLH-PAS: helix–loop–helix - per-arnt-sim 
CI: Complex I 
CII: Complex II 
CIII: Complex III 
CIV: Complex IV 
CN-PAGE: Clear Native PAGE 
CoQ: ubiquinone 
CS: citrate synthase 
Cys: Cysteine 
DAB: diaminobenzidine 
DCIP: 2,6-Dichlorophenolindophenol 
Dox: doxycycline 
DSB: double strand break 
EDTA: ethylenediaminetetraacetic acid 
ETC: Electron transport chain 
F-PCR: Fluorescent PCR 
FCCP: carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
FH: fumarate hydratase 
FIH-1: factor inhibiting HIF1 
FMN: Flavin mononucleotide 
GDH: glutamine dehydrogenase 
Gln: Glutamine 
Glu: Glutamate 
GLUT1: glucose transporter 1 
Gly: Glycin 
H2DCFDA: 2,7-dichlorodihydrofluorescein diacetate 
HDR: homology-directed repair 
HG: hydroxyglutarate 
HIF1: hypoxia inducible factor 1 
His: Histidine 
HMT: Human Metabolome Technologies 
HRE: hypoxic responsive elements 
IDH: isocitrate dehydrogenase 
Ile: Isoleucine 
IMM: Inner mitochondrial membrane 
IMS: Inter-membrane mitochondrial space 
LDHA: lactate dehydrogenase A 
Leu: Leucine 
Lys: Lysine 
MAS: malate aspartate shuttle 
MDH: malate dehydrogenase 
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Met: Methionine 
mtDNA: Mitochondrial DNA 
NHEJ: non-homologous end joining 
OAA: oxaloacetate 
OCR: Oxygen Consumption Rate 
OXPHOS: Oxidative phosphorylation 
PARP1: poly (ADP ribose) polymerase 1 
PCA: perchloric acid 
PD-module: distal half of the P module 
PDC: pyruvate dehydrogenase complex 
PDK: pyruvate dehydrogenase kinase 1 
PHD: prolyl hydroxylases 
Phe: Phenylalanine 
PP-module: proximal half of the P module 
Pro: Proline 
pVHL: Von Hippel Lindau protein 
QH2: ubiquinol 
rDNA: recombinant DNA 
ROS: Reactive oxygen species 
rRna: ribosomal RNA 
SA: succinate 
SDH: succinate dehydrogenase 
Ser: Serine 
SIRT: Sirtuin 
SRB: Sulforhodamine B 
SUCL: succinate Co-A ligase 
TALENs: transcription activator-like effector nucleases 
TCA: Tricarboxylic acid 
Th: Threonine; tRNA: transfer RNA 
Trp: Tryptophane 
TSG: Tumor suppressor gene 
Tyr: Tyrosine 
Val: Valine 
VEGF: vascular endothelial growth factor 
ZFNs: zinc finger nucleases 
ZFPs: Zinc finger proteins 
WT: wild-type 
α-KG: α-ketoglutarate 
α-KGDC: α-ketoglutarate dehydrogenase complex 
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Hallmarks of cancer 
 
Cancer cells are cells gone wrong. They have escaped the yet exceptionally effective genome 
maintenance systems that prevent pernicious mutations to occur, or else cells to thrive upon serious 
genetic damage. Thus, malignant cells display genome instability and obtain the capability to sustain 
chronic proliferation. Homeostasis of cell number is altered, and so are normal tissue architecture and 
function, ultimately threatening the life of cancer patients.  
At first enabled by an alteration in a so-called oncogene or tumor suppressor gene (TSG), the 
mutations found in the DNA sequence of a cancer cell have further accumulated during the 
progression of the tumor. As the lump grows, cells divide, a microenvironment settles and evolves, 
previously gained mutations are inherited and new ones emerge. This succession of genetic alterations 
in a changing environment implies that tumors are more than insular masses of proliferating cells. 
Cancer cells found with specific mutant genotypes have not only survived to the particular milieu, 
but the novel mutations that they harbour might have provided them with selective advantage, hence 
enabling their outgrowth, or merely their very existence. In this light, one can sense the parallel 
between Darwinian evolution and the underlying dynamic of cancer. In fact, malignant cells must 
acquire, through this selection procedure, a set of tailored solutions to sustain their proliferation and 
progression in the face of all opposition, from cell growth-and-division cycle control, to tumor 
microenvironment, and to body response. 
In 2000, Douglas Hanahan and Robert Weinberg have proposed that six hallmarks govern the 
transformation of normal cells to malignant cells. These are: sustaining proliferative signalling, 
evading growth suppressor, resisting to cell death, replicating immortally, acquiring blood supply, 
and invading and metastasizing (Hanahan and Weinberg, 2000). Because they are specific traits of 
cancer cells, they are also potential therapeutic targets as documented, for instance, by the broad use 
of chemo- and radio-therapies that take advantage of cancer cells high proliferation rate. Most 
recently, in 2011, the same authors have identified four newly emerging hallmarks: cancer cells 
7 
display genome instability and chronic inflammation, they evade immune destruction and they 
reprogram their energy metabolism (Hanahan and Weinberg, 2011) (Figure 1). These research areas 
are nowadays revealing tremendous promise for cancer treatment. 
 
 
Figure 1: Hallmarks of cancer (adapted from Hanahan and Weinberg, Cell, 2011) 
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Mitochondria as the cell powerhouses 
 
Complex life may have arisen from the endosymbiosis between an archaeon and a bacterium, which 
lately evolved into mitochondria (Lane and Pariseau, 2016). All eukaryotes have or have had 
mitochondria. Testifying its bacterial heritage, the mitochondrion presents with a circular DNA 
(mtDNA), a double membrane (Figure 2A), an independent translation machinery and, most 
importantly, the capacity to produce adenosine triphosphate (ATP), the cell energy currency. Indeed, 
the complex eukaryotic traits such as the presence of a nucleus, a larger genome, and the ability to 
form multicellular organisms rely on the fact that these cells possess powerhouses that greatly build 
on nutrient utilization for ATP production. In the cytosol, glycolysis can quickly and simply degrade 
a glucose molecule and transfer the energy contained into its chemical bonds into two high energy 
pyrophosphate bonds, forming two ATP. How mitochondria produce ATP is a far more complex 
mechanism. These organelles host the electron transport chain (ETC) embedded into their inner 
mitochondrial membrane (IMM) (Friedman and Nunnari, 2014). The ETC comprises several protein 
complexes that conduct an electron flow, allowing the latter to pump protons into the intermembrane 
mitochondrial space (IMS) against their concentration gradient. Protons subsequently move back into 
the matrix of mitochondria, flowing down through the ATP synthase that ultimately generates ATP. 
The all apparatus is the oxidative phosphorylation (OXPHOS) system that comprises four enzymatic 
complexes (CI-IV), two mobile electron carriers and the ATP synthase (Figure 2B). The complete 
mitochondrial oxidation of a single molecule of glucose provides 36 moles of ATP. To regulate 
energy transduction efficiency, mitochondria present with IMM invaginations called the “cristae”, 
whose surface area may be increased or decreased according to cell energetic requirements (Mannella 
et al., 2013). 
Among the 87 polypeptides that constitute the OXPHOS system, only 13 are encoded by the mtDNA 
(Figure 2C and D), while the remaining part is encoded at the nuclear level and later imported into 
the mitochondria (Harbauer et al., 2014). The mtDNA, comprised of 16.569 base pair, is double-
stranded and is localized in the matrix of mitochondria, where it is present in high copy number, 
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ranging from tens to thousands copies per cell. The number of mitochondria per mammalian cells 
vary and may reach more than 2000 in some tissues. Importantly, mtDNA tends to accumulate 
mutations at a much higher rate than nuclear DNA (Liu and Demple, 2010). Indeed, the mitochondrial 
genome lacks protective histones, introns and efficient DNA repair system, and it is at the immediate 
vicinity of the ETC that produces reactive oxygen species (ROS). The phenotypic property and 
severity induced by a mutation in mtDNA depends on the nature of the mutation and on the proportion 
of mutant and wild-type mtDNAs present in the cell. When cells contain a mixture of wild-type and 
mutant mtDNAs, this situation is referred to as heteroplasmy. Instead, when all copies of the mtDNA 
are identical, this condition is termed homoplasmy.  
Figure 2: Mitochondria hosts the respiratory chain and multiple copies of DNA 
(A) Overview of the mitochondrial structure with the cristae invaginations into the matrix, which 
contains multiples copies of mtDNA. The OXPHOS system is embedded into the inner membrane of 
mitochondria. (B) Representation of the OXPHOS system. The electron transport chain comprises 
four complexes (CI-IV) that drive an electron flux allowing CI, CIII and CIV to pump protons into 
the inter-membrane space. The ATP synthase produces ATP when protons move back to the matrix. 
(C) The mitochondrial DNA is circular and encodes for complexes subunits, transfer RNA (tRNA) 
and ribosomal RNA (rRNA). (D) Constituents of the OXPHOS system and their origins (nuclear or 
mitochondrial genome) (Smeitink et al., 2001). 
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Cancer metabolism 
 
The Warburg hypothesis revisited 
 
Although metabolic reprogramming has been only recently recognized as an emerging hallmark, 
cancer metabolism is one of the oldest area of research in cancer biology, even predating the discovery 
of oncogenes and tumor suppressors by some 50 years (Lodish et al., 2000). In the early 20th century, 
Otto Warburg demonstrated for the first time that cancer and normal cells differ from each other by 
their metabolic phenotype, the first ones exhibiting an increased glycolytic metabolism regardless the 
oxygen supply (i.e. aerobic glycolysis). He hypothesized that cancer cells shift their metabolism 
towards glycolysis because of an accumulation of defective mitochondria, thus preventing the use of 
OXPHOS as the major contributor for ATP generation (Warburg et al., 1927). Supporting the latter 
hypothesis, mtDNA mutations have been associated to the upregulation of glycolytic enzymes and to 
cancer progression (Cuezva et al., 2002; Kirches, 2009; Sánchez-Aragó et al., 2010), and positron 
emission tomography imaging confirmed the increase in glucose flux in the vast majority of tumors 
in vivo (Zhu et al., 2011). However, while the field of cancer metabolism built on Otto Warburg’s 
work, it also prompted his hypothesis to be revisited. More complex bioenergetic traits have emerged 
from studies, which clearly demonstrate that increased glycolysis is only rarely the result of 
mitochondrial dysfunction. Most cancer cells still maintain a significant level of OXPHOS in vitro 
and in vivo (Jose et al., 2011; Marin-Valencia et al., 2012; Smolková et al., 2011; Wolf, 2014; Zu and 
Guppy, 2004). Further, while glycolysis general enhancement may directly quench oxidative 
metabolism in certain types of cancer (Conley et al., 2001; Crabtree, 1929; Rodríguez-Enríquez et 
al., 2010), glucose deprivation may instead increase mitochondrial function in cancer cells (Smolková 
et al., 2010). The latter findings support the fact that OXPHOS may be beneficial to cancer cells, 
especially in condition of nutritional limitation. 
Glycolysis is known to sustain rapid cell division. As a matter of fact, several non-transformed cells 
display a high glycolytic phenotype during fast proliferation (Lunt and Vander Heiden, 2011). In 
cancer, enhanced glycolytic machinery has been shown to foster synthesis of nucleotides, fatty acids 
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and non-essential amino acids for biomass production, to generate energy and reductive equivalents, 
and to enable metastasis, local invasion and antitumor immunity through lactate production (Chen et 
al., 2015; Gatenby and Gillies, 2004) (Figure 3). Not surprisingly, numerous studies revealed that 
oncogenes activation and loss of TSGs directly or indirectly increases glycolysis (Dang, 2012; 
DeBerardinis et al., 2008; Jones and Thompson, 2009) (Figure 3). Hence, aerobic glycolysis may 
preferentially be selected by cancer cells as it provides them with substantial growth advantages, 
making it an attractive target for cancer therapy (Vander Heiden, 2011).  
 
Figure 3: The glycolytic pathway within cell metabolism 
Glycolysis is directly controlled by signalling pathways involving known oncogenes and TSGs. This 
scheme shows how glycolysis, oxidative phosphorylation and biosynthetic pathways are 
interconnected and regulated. In cancer, the glycolytic pathway is stimulated as it provides new 
biomass for cell proliferation and lactate for invasion and metastasis. In hypoxia, glycolysis is further 
stimulated and is disconnected from OXPHOS, pyruvate being mainly redirected toward lactate 
production. The transcription factor hypoxia inducible factor 1 (HIF1) is the major regulator of 
glycolytic upregulation in hypoxia and acts at different levels in the glycolytic pathway. Expression 
of HIF1, AKT, P53, AMPK, Myc and Ras are associated with enhanced glycolysis in cancer.  
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The environment matters: Hypoxia and the HIF1-signalling 
 
A common feature of solid tumors is that their growth rate often exceeds the speed of new vessels 
formation and therefore cells rapidly accumulate in poorly vascularized bulks (Jain et al., 2002). 
Hence, cancer cells cope with fluctuations in oxygen and nutrients levels, which force them to 
optimize substrate utilization by adjusting metabolic pathways, ultimately allowing them to keep 
meeting the requirements for malignancy. While nutrient scarcity leads to OXPHOS enhancement 
and promotes mitochondrial biogenesis (Martin-Montalvo and de Cabo, 2013; Smolková et al., 2011), 
hypoxia instead induces a typical “Warburg-like” shift from OXPHOS to glycolysis. Hence, an 
already existing reliance on glycolysis can be further increased when cancer cells face low oxygen 
tension. The transcription factor hypoxia inducible factor 1 (HIF1) is the master regulator of the 
hypoxic response and it mediates the complex hypoxic adaptation by modulating the expression of 
hundreds of genes (Semenza, 2007). HIF1 is composed of an α- and a β-subunit, belonging to the 
basic helix–loop–helix - per-arnt-sim (bHLH-PAS) protein family, both constitutively produced. In 
condition of normal oxygen tension (normoxia), HIF1α is hydroxylated on two specific prolyl 
residues (P402 and P564) in its oxygen-dependent degradation domain by three different prolyl 
hydroxylases: PHD 1, 2 and 3. This in turn recruits an E3 ubiquitin ligase complex containing the 
von Hippel Lindau protein (pVHL), resulting in HIF1α ubiquitylation and subsequent degradation by 
the proteasome (Figure 4). PHDs are Fe(II)/αKG-dependent dioxygenases that use the mitochondrial 
metabolite α-ketoglutarate (α-KG) and O2 as co-substrates, and require Fe (II) as a cofactor to produce 
succinate (SA) and CO2 (McDonough et al., 2010). Noticeably, even in the absence of oxygen, high 
levels of α-KG are sufficient to promote the activity of PHDs, making the metabolite an important 
modulator of the hypoxic response (Tennant et al., 2009). In hypoxia, PHDs low affinity for oxygen 
does not allow them to hydroxylate HIF1α, which cannot be degraded and becomes stabilized. In this 
context, HIF1a and HIF1b dimerize to form the transcription factor HIF1 that subsequently 
translocates into the nucleus (Depping et al., 2008). The modification of genes expression in hypoxia 
involves the formation of a DNA-binding complex that contain both HIF1 and the pair of transcription 
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adaptors p300/CBP, which altogether bind DNA at conserved promoter and enhancer-linked HIF1 
sites, as hypoxic responsive elements (HRE) (Arany et al., 1996) (Figure 4). Of note, the factor 
inhibiting HIF1 (FIH-1), another Fe(II)/αKG-dependent dioxygenase, can hydroxylate the asparagine 
N803 of HIF1 and thereby block its interaction with the coactivators p300/CREB or CBP, making it 
an important modulator of the hypoxic response. The latter includes an attempt to increase 
vascularization and glycolytic machinery, to get sufficient oxygen levels back and to survive 
anaerobic conditions, respectively. Hence, genes such as the vascular endothelial growth factor 
(VEGF), lactate dehydrogenase A (LDHA), pyruvate dehydrogenase kinase 1 (PDK), and glucose 
transporter 1 (GLUT1), among many other glycolytic enzymes, are upregulated in hypoxia upon 
HIF1 activation. 
 
Figure 4: Mechanisms that regulate HIF1 activation (adapted from (Denko, 2008) 
HIF1α hydroxylation on P402 and P564 by the prolyl-hydroxylases (PHDs) induces its ubiquitination 
by the Von-Hippel-Lindau ubiquitin ligase complex (VHL), and its subsequent degradation by the 
proteasome. The factor inhibiting HIF1 (FIH) may hydroxylate HIF1α on N803, thereby preventing 
its activation. PHD and FIH are promoted by Fe(II), O2 and α-KG. When stabilized, HIF1α 
heterodimerizes with HIF1b and the p300/CBP complex to bind the hypoxia responsive element 
(HRE) at the promoter of genes, hence fostering their expression.  
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Besides HIF1a, two other members of the bHLH-PAS superfamily, HIF2a and HIF3a, have also 
been described. While the role of HIF2a in the hypoxic response has been well established, the 
mechanisms of action of HIF3a are still poorly understood. HIF1a and HIF2a are closely related and 
they both activate HRE-dependent gene expression. However, the two transcription factors differ in 
their transactivation domains and may therefore bind different co-factors and affect the expression of 
distinct target genes (Loboda et al., 2010). Furthermore, while HIF1a is ubiquitously expressed, 
HIF2a expression is limited to certain tissues. The latter also presents with different roles in cancer, 
which may negatively or positively influence tumor progression according to tumor type (Cho and 
Kaelin, 2016; Favier et al., 2007; Loboda et al., 2010). 
Numerous cancer-associated genetic alterations promote HIF1 expression and/or stabilization. Both 
the overexpression of oncogenes RAS, V-SRC, stimulation of the PI3K/AKT/mTORC1 axis, and 
loss of the tumor suppressors pVHL, PTEN and p53 have been shown to increase HIF1 levels (Lim 
et al., 2004; Semenza, 2013) (Figure 4). Similarly, several mitochondrial dysfunctions can further 
stimulate HIF1 activation. Indeed, ROS were shown to participate to the hypoxia-mediated 
stabilization of HIF1a (Chandel et al., 2000), suggesting that pathological levels of ROS in cancer 
may also affect the hypoxic response, independently from O2 concentration. Accordingly, several 
mechanisms through which ROS could affect the HIF1-signalling have been proposed, all of which 
likely to conspire to promote the transcription factor’s activity and thereby the tumorigenic potential 
of cancer cells (Galanis et al., 2008).  
Contribution of mitochondrial metabolism to cancer progression 
 
In the canonical view, the tricarboxylic acid (TCA) cycle is a series of chemical reactions that take 
place in the mitochondrial matrix and drive the oxidation of carbon fuels derived from acetyl-CoA 
(Ac-CoA), which is mainly provided by glycolysis and fatty acid oxidation. These reactions produce 
the reducing equivalents NADH and FADH2 that are subsequently utilized by respiratory CI and 
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respiratory CII, respectively, to generate the mitochondrial membrane potential (Δψm) required for 
ATP production (Figure 5).  
 
 
Figure 5: The TCA cycle  
The acetyl fraction of Ac-CoA moiety is condensed with oxaloacetate (OAA) by the citrate synthase 
(CS) to form citrate. The aconitase (ACO) isomerizes citrate into isocitrate, which is then 
decarboxylated into α-KG by the isocitrate dehydrogenase (IDH) 3. In the second part of the TCA 
cycle, succinyl Co-A, produced by the second and last decarboxylation reaction, performed by the α-
KGDC, is converted back to oxaloacetate through several steps involving production of SA by 
succinate Co-A ligase (SUCL) and fumarate, malate and finally oxaloacetate by, respectively, 
succinate dehydrogenase (SDH), fumarate hydratase (FH) and malate dehydrogenase (MDH). 
Glutamine feeds the TCA cycle at α-KG level. Glucose and fatty acids feed the TCA cycle at Ac-CoA 
level. The NADH and FADH2 produced by the TCA cycle are utilized by respiratory CI and CII, 
respectively. TCA metabolic flux is represented by blue arrows ( ). 
 
Yet, the TCA cycle exhibits manifold other functions that shape the metabolic profile of cancer cells 
and influence tumor progression. Glutamine, the most abundant amino acid in plasma, has been 
widely described as an additional key source of both carbon and nitrogen, especially for rapidly 
dividing cells (Hosios et al., 2016). Glutamine fuels the TCA cycle at α-KG level, which can enter 
both energetic and biosynthetic pathways. Indeed, α-KG may either be oxidized by the α-
ketoglutarate dehydrogenase complex (α-KGDC) inside mitochondria, or it may be reduced, hence 
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pushing the TCA cycle towards citrate (DeBerardinis et al., 2007). The latter can be shuttled to the 
cytosol where it may be converted back into Ac-CoA, which is subsequently used for lipid 
biosynthesis. This glutamine-dependent biosynthetic pathway is promoted in cancer cells that cope 
with a low oxygen environment or which exhibit OXPHOS deficiency (DeBerardinis et al., 2007; 
Fendt et al., 2013; Mullen et al., 2014; Wise et al., 2011). In particular, hypoxia induces a block in 
glucose and fatty acid oxidation, caused by the inhibition of Ac-CoA entry into the TCA cycle (Huang 
et al., 2014; Lu et al., 2008). In this context, citrate is generated from glutamine through a TCA cycle 
running in a reverse manner. Constitutive activation of HIF1 has been shown to promote the rewiring 
of α-KG fate from oxidative to reductive metabolism in normoxia (Metallo et al., 2011; Wise et al., 
2011), highlighting the important role of the transcription factor in modulating TCA metabolites 
levels (Figure 6). HIF1 reduces the activity of both PDH and α-KGDH, hence likely to contribute to 
elevating the α-KG/citrate ratio in cells and to promote α-KG reductive carboxylation, by mass action 
on the TCA cycle flux (Fendt et al., 2013; Sun and Denko, 2014). More recently, HIF1 has also been 
shown to promote the expression of the glutamine dehydrogenase (GDH), which converts glutamate 
to α-KG (Jiang et al., 2017). Although Jiang and colleagues demonstrated the importance of the 
HIF1α-GDH axis for ATP production in hypoxia, its involvement in providing α-KG for reductive 
carboxylation is however very likely. 
Thus, even respiration impairment does not imply a complete shutoff of mitochondrial metabolism. 
The TCA cycle is fuelled by substrates entering at different gateways and provides the carbon source 
for both energy production and biosynthesis. 
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Figure 6: Molecular actors driving α-KG reductive carboxylation in mitochondria upon 
hypoxia (Adapted from Vatrinet et al., Cancer & Metab, 2017) 
Under hypoxia, NADH and HIF1 inhibit the enzymes α-KGDC and PDH, thereby increasing the α-
KG/citrate ratio. Besides, ROS production may further participate to the latter by inhibiting the α-
KGDC and the aconitase. Anaplerotic source of α-KG may be fostered through the HIF1-mediated 
increase in GDH activity. TCA metabolic flux is represented by blue arrows ( ). 
 
Further, mutations in several TCA cycle enzymes, including mutations in fumarate hydratase (FH), 
succinate dehydrogenases (SDH) and isocitrate dehydrogenase 1 and 2 (IDH1/2) have been reported 
in multiple types of cancer, which respectively accumulate SA, fumarate, and (R)-2-hydroxyglutarate 
(HG), all conveying broad oncogenic signals. These so called “oncometabolites” share great 
structural and metabolic similarity to α-KG, retaining therefore the capacity to regulate Fe(II)/αKG-
dependent dioxygenases (Morin et al., 2014), likely to influence on HIF1-signalling through the 
modulation of PHDs and FIH activity. Accordingly, PHDs are allosterically inhibited by SA and 
fumarate (Selak et al., 2005), while (R)-2-HG occupies α-KG’s binding site and acts as a competitive 
inhibitor (Xu et al., 2011). Furthermore, chronic inhibition of PHDs in both SDH-deficient and FH-
deficient tumors is associated with the stabilization of HIF1α and activation of downstream hypoxic 
pathways, even in normoxia (i.e. pseudohypoxia) (Pollard et al., 2005). Contrariwise, α-KG is 
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sufficient to oppose SA, fumarate, and hypoxia-mediated activation of HIF1α, resulting in the 
reversal of enhanced glycolysis and cell death (MacKenzie et al., 2007; Tennant et al., 2009). The 
Fe(II)/αKG-dependent dioxygenases are a family of more than 60 enzymes involved in nutrient 
sensing, oxygen sensing, and epigenome editing (Loenarz and Schofield, 2008; Rose et al., 2011). 
The KM of Fe(II)/αKG-dependent dioxygenases for α-KG is close to its physiological concentration. 
Therefore, even a modest variation in the α-KG levels may profoundly modify dioxygenases-
mediated signals. In this light, and building on ours and others precedent studies, our group has 
recently hypothesised an essential role for the α-KG signal in continuously restructuring the metabolic 
and epigenetic landscape of cancer cells to survive internal and environmental pressures (Vatrinet et 
al., 2017).  
Hence, mitochondria are not bystanders in the process of carcinogenesis and tumor progression. Far 
from being only the powerhouses of cells, these organelles are the hub of multiple metabolic pathways 
and the source of signalling metabolites whose levels can significantly impact on cancer cells fate 
within tumors.  
 
What did we learn from oncocytomas? 
 
Oncocytomas are low proliferative tumors named after their characteristic of bearing oncocytes’ 
mitochondria, which display aberrant cristae and show low electron density on micrographs, thus 
being most likely non-functional. Accordingly, oncocytic tumors share the common but rare feature 
that they harbour high burden of disruptive mutations in mitochondrial genes encoding for OXPHOS 
complexes subunits (Gasparre et al., 2011a). Instead, such severe mtDNA mutations have been shown 
to be purified in aggressive cancer, where they are often found at low heteroplasmy levels (Iommarini 
et al., 2013; Ju et al., 2014; Kurelac et al., 2015; Pereira et al., 2012). 
In a recent review published by our group, De Luise et al. identified three factors that must be reached 
in order to achieve the oncocytic phenotype (De Luise et al., 2017)., namely: i) a lesion hitting the 
mitochondrial energy production capacity, which triggers a bioenergetics crisis; ii) an imbalance 
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between mitochondrial biogenesis and autophagy/ mitophagy, which may predispose to the 
accumulation of damaged organelles; iii) the contribution of oncogenes/TSGs/modifier genes to the 
onset of the previous two conditions. Strikingly, mutations were often found in genes encoding CI 
subunits. In most cases, they were stop codon or frameshift mutations, known to disrupt the assembly 
of the multisubunit complex whose activity was found substantially reduced (Mayr et al., 2008; 
Simonnet et al., 2003; Zimmermann et al., 2011). For instance, while low heteroplasmy levels of a 
MT-ND5 mutation were observed in several cancer types (Brandon et al., 2006; Larman et al., 2012; 
Pereira et al., 2012), the homoplasmic variant was only found in oncocytic tumors (Gasparre et al., 
2009). In this light, and given the low aggressiveness of oncocytic tumors, the potential anti-
tumorigenic effect of CI loss ought to be further investigated.  
 
The mitochondrial respiratory Complex I  
 
The complex I within the respiratory chain  
 
The mammalian CI (NADH:ubiquinone oxidoreductase) is the first and largest complex of the 
respiratory chain and is comprised of 45 subunits that are encoded by both nuclear and mitochondrial 
DNA (Hirst, 2013). Seven subunits are encoded by the mitochondrial genome and synthesized on 
mitochondrial ribosomes. The 38 remaining subunits are encoded by the nuclear genome and 
synthesized on cytoplasmic ribosomes (Koopman et al., 2009). CI has a L-shaped structure with one 
hydrophobic arm embedded into the inner membrane and one hydrophilic arm pointing into the 
matrix (Zhu et al., 2016) (Figure 7). The multi-subunit complex can be subdivided into three 
structurally and functionally defined modules: the N-module (NADH binding and oxidation), the Q-
module (transfer of electrons to ubiquinone), and the P-module (proton pumping). The role of CI is 
to oxidize the NADH produced by mitochondrial dehydrogenases and malate aspartate shuttle 
(MAS), both dependent on TCA cycle and glycolytic flux rates. Flavin mononucleotides (FMN) 
mediate the electron transfer along a chain of FeS clusters to the terminal cluster and to ubiquinone 
(CoQ) that is consequently reduced to ubiquinol (QH2). This process allows 4 protons to be pumped 
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from the mitochondrial matrix into the intermembrane space (IMS). QH2 is subsequently oxidized in 
CoQ by complex III to reduce cytochrome c, concomitantly with the release of 4 additional protons 
into the IMS. Finally, complex IV uses cytochrome c to reduce molecular oxygen, the final electron 
acceptor, releasing 2 protons into the IMS (Figure 2B). The electrochemical proton gradient provided 
ultimately allows ATP production as the protons accumulated in the IMS flow back through the ATP 
synthase into the matrix of mitochondria (Nelson and Cox, 2017). 
 
Figure 7: Structure of the mammalian respiratory complex I (Zhu et al., Nature, 2016) 
Overview of the complex with 31 supernumerary subunits (in red) that are wrapped around a core 
of 14 subunits (in blue). FeS clusters are found in the hydrophilic arm (in yellow/orange). 
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Complex I assembly 
 
Functional CI requires a multifaceted and coordinated process of assembly (Guerrero-Castillo et al., 
2017) (Figure 8). Briefly, the assembly of the different modules are initiated separately. An 89 kDa 
complex containing the subunits NDUFS2 and NDUFS3, and the accessory subunit NDUFA5, is 
formed as a preliminary Q module, around which converge the remaining subunits of the Q module 
together with additional subunits of the proximal half of the P module (PP-module), to form a larger 
complex with predicted mass of 283 kDa. 
The PP-module consists initially of 3 core subunits that bind 4 assembly factors, which subsequently 
accumulate 3 additional subunits and assembly factors. This 386 kDa complex subsequently bind a 
part of the distal half of the P module (PD-module), and then the entire Q module associated to the 
remaining subunits of the PP-module. 
The PD-module arises from the assembly of two separate subcomplexes with predicted mass of 230 
kDa and 154 kDa, with the first one originating from the accumulation of further subunits around a 
smaller complex of 53 kDa. The two blocks bind each other only after the 230 kDa subcomplex has 
combined with the large complex introduced above, containing both the PP and Q modules. 
The N module is the last constituent of CI. It comprises 8 subunits, which arise from the initial 
convergence of two subcomplexes of two subunits, which subsequently bind a larger complex that 
comprises 4 subunits, together with the rest of the respiratory CI. 
Studying CI assembly and its regulation is challenging, but it provides essential knowledge to 
understand genotype to phenotype correlation in disease, to provide diagnosis and to elaborate 
therapeutic strategy. On the other hand, studies point to the crucial role of specific subunits for CI 
architecture and function. Noticeably, NDUFS3 is of great interest. Not only this subunit is involved 
in the very early phases of CI assembly, but it is a core constituent of the Q module, at the interface 
between the P and N modules, and thereby between the hydrophilic and hydrophobic arms. In this 
light, the removal of NDUFS3 would most likely induce CI disassembly. 
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Figure 8: Comprehensive model of CI assembly (Guerrero-Castillo et al., 2017) 
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Complex I: a modulator of tumor progression  
 
CI activity and dysfunctions are reflected on the cellular redox state, energetic status and intracellular 
oxygen levels, all impacting on tumor progression (Figure 9) (Vatrinet et al., 2015). 
 
 
Figure 9: The mechanisms by which CI modulate tumor progression (adapted from Vatrinet et 
al., The IJBCB, 2015)  
CI activity influences ROS levels, NADH/NAD
+
 and AMP/ATP ratios, and oxygen and TCA 
metabolites levels. This scheme illustrates the crucial position of HIF1α, whose stabilization may be 
regulated by all the actors cited above. Besides, signalling pathways such as AMPK, PI3K, MAPK, 
Sirtuins and PARP1 may indirectly be regulated by CI function, thereby impacting on key 
mechanisms that drive cancer progression. 
 
Complex I, ROS production and oxygen consumption 
 
ROS are by-products of mitochondrial oxidative metabolism and, at physiological concentration, they 
are crucial for cell survival (Murphy, 2009). They include the superoxide anion (O.2-), hydrogen 
peroxide (H2O2), and the hydroxyl radical (OH.). The O2 consumed (0.1- 0.5%) by mitochondria is 
converted into O.2- (Giorgio et al., 2007), which is rapidly and spontaneously converted into H2O2 
(Wang et al., 2008). In turn, ROS regulate several mechanisms essential for normal cell function such 
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as protein turnover, posttranscriptional modification of proteins, transcriptional regulation, and 
modifying redox-sensitive enzymes activity and protein interactions (Trachootham et al., 2008). In 
contrast, when a situation of oxidative stress is reached, H2O2 and O
.
2
- give rise to OH·, in presence 
of reduced transition metal (Murphy, 2009). 
ROS levels are a reliable indicator of ETC damage and their overproduction may participate to cancer 
progression by inducing genomic instability, modifying gene expression and acting as regulatory 
molecules (Ray et al., 2012; Szatrowski and Nathan, 1991), or they may induce cell death when 
chronically oversupplied (Shen and Liu, 2006). The two main producers of O· in mitochondria are 
the CI and the α-KGDC, which are also targets of ROS that inhibit both enzymes in a reversible 
manner. Importantly, CI and α-KGDC activity and ROS generation depend on the mitochondrial 
NAD+/NADH ratio (Adam-Vizi and Chinopoulos, 2006), indicating a functional link between the 
two-enzymatic complex.  
Importantly, hypoxia induces mitochondrial ROS production, which have been shown to participate 
to cell metabolic adaptation by promoting the HIF1 signalling pathway (Chandel et al., 1998). 
Although contradicting with the dependence of mitochondrial O.2- production to oxygen 
concentration, it has been proposed that upon hypoxia, changes in [NO.] may change the redox state 
of the cytochrome oxidase and therefore CIII response to low oxygen levels, thereby increasing H2O2 
production. In fact, loss of cytochrome c or Rieske FeS center of CIII eliminates ROS generation 
(Guzy et al., 2005). Other mechanisms through which hypoxia increases H2O2 production have been 
proposed, such as through cell signalling pathway, but further investigation are needed to clarify the 
phenomenon (Murphy, 2009). In turn, several processes through which ROS mediate HIF1 activation 
have been described. On the one hand, H2O2 may induce the conversion of Fe2+, substrate of the 
PHDs, into Fe3+, thereby inactivating the dioxygenases and resulting in HIF1α stabilization 
(Pouysségur and Mechta-Grigoriou, 2006). On the other hand, ROS may promote several signalling 
pathways, such as PI3K/Akt and p38 MAPK, which all may inactivate PHDs (Emerling et al., 2005; 
Mottet et al., 2003).  
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Recent studies suggest that the role of CI in the interplay between ROS and HIF1 is essential for the 
hypoxic response. While CI may promote ETC activity and thereby ROS promotion under hypoxia, 
HIF1 has instead been shown to promote the expression of NDUFA4L2, subunit of the CI, thus 
reducing the activity of the enzymatic complex and thereby lowering ROS production in 
hepatocellular carcinoma cell lines. Contrariwise, inactivation of the HIF1/NDUFA4L2 axis resulted 
in ROS accumulation and apoptosis (Lai et al., 2016). The importance of this CI subunit in 
coordinating the hypoxic response has been discovered only very recently (Tello et al., 2011). In 
2016, four separate studies have identified NDUFA4L2 as a marker of poor prognosis in cancer 
patients (Lai et al., 2016; Liu et al., 2016; Lv et al., 2016; Minton et al., 2016). 
Hence, CI plays a pro-active role in the multiple ROS-mediated mechanisms of cancer cells. 
Importantly, while mild CI dysfunction may induce a severe oxidative stress and contribute to tumor 
progression and metastasis (Ishikawa et al., 2008; Sharma et al., 2011), strong CI impairment may 
instead not be associated to a significant increase in ROS production, due to the lack of the FMN sites 
where ROS are generated (Gasparre et al., 2011b; Iommarini et al., 2014). 
Additionally, increased evidences point to mitochondrial oxygen consumption as an additional potent 
modulator of tumor progression. Indeed, the concentration of oxygen in cells does not only depend 
on its delivery, and therefore on extracellular oxygen levels, but it is also defined by the rate of its 
conversion into H2O by CIII, and therefore by ETC activity. Oxygen is a signalling molecule, as it 
influences the activity of several oxygenases, including the Fe(II)/αKG-dependent dioxygenases 
(Loenarz and Schofield, 2008). Inhibiting CI may reduce HIF1α stabilization in hypoxia by increasing 
oxygen tension and promoting PHDs activity (Bastian et al., 2017). Further, several studies have 
shown that decreased oxygen consumption impairs the hypoxia-mediated resistance to radiotherapy 
of cancer cells (Gallez et al., 2017). In line with this, inhibiting CI has been shown to improve the 
oxygenations of tumors and therefore their radiosensitivity (Zannella et al., 2013). 
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Complex I and the cellular energetic status  
 
Increasing evidence shows that cellular energetic crisis may impact on cancer progression. Given the 
pivotal role of CI in ETC function, defects in the enzyme activity are likely to affect cancer cells 
energetic status and metabolism, narrowing the possibilities of nutrient utilization for ATP 
production. As a matter of fact, cells with mitochondrial dysfunction are more sensitive to low 
glucose conditions and calorie restriction, and combination of complex I inhibition and glucose 
deprivation might be selectively lethal for cancer cells (Agarwal et al., 2016; Bikas et al., 2015; Birsoy 
et al., 2014; Guo et al., 2011; Morscher et al., 2015). Energetic crisis is translated to cells through the 
energy sensor AMP activated kinase (AMPK), which inhibits biosynthetic pathways and supports 
catabolic events in order to restore intracellular energetic balance (Hardie et al., 2012). We recently 
showed that CI-defective cancer cells displayed a clear-cut increase in AMP/ATP ratio and AMPK 
activation under metabolic stress conditions (Iommarini et al., 2014). It has been shown that AMPK 
activation represses mTORC1 signalling, thereby preventing cell growth and proliferation, and 
suppressing HIF1α translation (Faubert et al., 2013). Consistent with this, lack of AMPK enhanced 
glycolysis in a HIF1-dependent mechanism, suggesting that AMPK acts as a tumor suppressor by 
repressing HIF1-signalling (Faubert et al., 2013).  
 
Complex I and the NAD+/NADH ratio 
 
The NAD+/NADH ratio regulates several metabolic routes and signalling pathways that greatly 
impact on cancer progression. Importantly, cancer cells may exhibit a dependency on metabolic 
pathways regulated by NAD+ (Gui et al., 2016; van Horssen et al., 2013). Recently, studies have 
demonstrated that an essential role of the respiratory chain is indeed to transfer electrons from NADH 
to oxygen, thereby maintaining an adequate redox state that allows aspartate synthesis and therefore 
cancer proliferation (Birsoy et al., 2015; Sullivan et al., 2015). In line with this, the NADH/NAD+ 
ratio would correlate with tumor growth in vivo (Gui et al., 2016). In this light, lower CI-mediated 
NADH oxidation may negatively affect cancer cell proliferation. Accordingly, Vander Heiden’s 
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group showed that the effects of CI inhibition on the tumorigenic potential of various cancer cells 
may depend on their reliance on NAD+ synthesis and aspartate production. These metabolic 
exigencies may vary broadly with environment changes, which would therefore determine cancer 
cells sensitivity to CI inhibition (Gui et al., 2016).  
Conversely, it has been shown that maintaining a minimal concentration of NADH is essential for 
reductive carboxylation to operate. This is explained by the requirement of cancer cells with 
respiratory defects to transfer reducing equivalent from NADH to NADPH, a reducing agent that 
subsequently drive citrate production from α-KG, thereby maintaining cell proliferation (Mullen et 
al., 2014). 
Further, an unbalanced NADH/NAD+ ratio may also affect Sirtuins (SIRTs)-dependent signalling 
pathway and the poly (ADP ribose) polymerase 1 (PARP1) control of DNA integrity and cell 
proliferation (Chiarugi et al., 2012). The role of PARP in promoting tumor progression is well known, 
as it sustains aberrant DNA repair mechanism (Davar et al., 2012), and five PARP inhibitors are now 
in late-stage development in clinical trials (Dulaney et al., 2017). In contrast, although all the seven 
Sirtuins (SIRT1-7) have been shown to be involved in cancer, their precise roles and influences on 
tumor progression ought to be clarified (George and Ahmad, 2016). While SIRT1 overexpression 
reduces the formation of carcinomas and sarcomas (Herranz and Serrano, 2010), it has also been 
found highly expressed in other cancers (Yuan et al., 2013a), where it would promote carcinogenesis 
and resistance to chemotherapy (Herranz and Serrano, 2010; Liang et al., 2008). Mitochondrial 
SIRT3 and SIRT5 have also been found overexpressed in different cancer types (Alhazzazi et al., 
2011a, 2011b; Lu et al., 2014). Nevertheless, the latter were also shown to be down-regulated in other 
tumors (Lai et al., 2013; Yang et al., 2014), where they might act as tumor suppressors by regulating 
ROS production and hypoxic response (Finley et al., 2011). SIRT4 would instead act exclusively as 
a tumor suppressor by restricting glutamine utilization and repressing Myc-induced B cells 
lymphomagenesis (Jeong et al., 2016). 
Lastly, variations of the NADH/NAD+ ratio directly influence TCA fluxes and metabolites levels. 
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NADH allosterically regulates the activity of the TCA cycle checkpoints pyruvate dehydrogenase 
complex (PDC), IDH 3, and α-KGDC. In respiration-defective cancer cells, the accumulation of 
NADH may inhibit these enzymes while promoting the activity of the NADPH-dependant IDH1/2, 
consequently fostering the reductive carboxylation of α-KG. Increase in cellular NADH levels may 
also promote the activity of the MDH 1 and 2, the phosphoglycerate dehydrogenase and LDHA. In 
this context, the latter enzymes may consume rather than produce NADH, together with converting 
the accumulating α-KG into L-2HG, hence re-equilibrating cellular redox state and shaping signalling 
pathways to adapt both cell metabolic and epigenetic landscape (Vatrinet et al., 2017). Accordingly, 
NADH accumulation may lead to an increase in cytosolic α-KG levels through α-KGDC inhibition. 
In this frame, our group has shown that CI-defective cancer cells displayed an unbalanced 
NAD+/NADH ratio together with an accumulation of α-KG, associated to a constitutive 
destabilization of HIF1a (Calabrese et al., 2013; Gasparre et al., 2011b; Iommarini et al., 2014) 
(Figure 10). These cells were unable to enhance the glycolytic machinery during hypoxia and 
displayed a lower tumorigenic potential in vitro and in vivo compared to CI competent cancer cells 
(Calabrese et al., 2013).  
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Figure 10: Metabolic changes in the absence/recovery of functional CI in cancer cells 
(Calabrese et al., 2013) 
The increase in the α-KG/SA ratio that is associated to the lack of CI may foster the activity of the 
PHD, hence destabilizing HIF1α (left panel). Inactivation of HIF1α prevents the upregulation of the 
glycolytic machinery normally requested to compensate for the defective mitochondrial respiration. 
This scenario may not allow the metabolic adaptation of tumor cells, possibly inducing a short-
circuited mitochondrial compensatory proliferation. CI rescue recovers NADH consumption and 
therefore the α-KG/SA balance (right panel). In this scenario, HIF1α remains stabilized and may 
therefore translocate into the nucleus where it dimerizes with HIF-1β and activate transcription of 
target genes (red ovals and rectangles), among which those contributing to increase the glycolytic 
flux. Red elements indicate activation or overexpression.  
 
 
Hence, CI might affect tumorigenesis and cancer progression through different mechanisms. 
Modulating CI activity influences ROS production, oxygen consumption rate, NADH levels and 
usage, ATP generation, metabolic pathways utilization, and the amount of signalling metabolites. 
Various degrees of CI dysfunctions have been shown to differently affect tumor progression 
(Iommarini et al., 2014; Park et al., 2009). Accordingly, not all nDNA-encoded CI core subunits 
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defects have equal prognostic significance and may instead have opposite effects (Ellinger et al., 
2016; Su et al., 2016). Furthermore, beside the severity of CI impairment, the effect may also be 
context dependant. In fact, although loss of CI is associated to low-tumorigenic potential (Calabrese 
et al., 2013), it might help SDH-mutant tumors to survive by promoting glutamine metabolism 
(Lorendeau et al., 2016). This recent study further accentuates the oncojanus role of CI as previously 
defined by our group (Gasparre et al., 2011b). Overall, considering the essential role of CI in 
controlling metabolism, hypoxic adaptation and cell proliferation, this enzyme may be envisioned as 
a target for the development of new adjuvant anticancer therapies. 
Targeting Complex I 
 
Pharmacological compound 
 
Several compounds affecting CI have been studied as anticancer drugs (Table 1). The plant alkaloid 
rotenone, piericidin A and capsaicin are specific inhibitors of CI and have been shown to be 
selectively cytotoxic for cancer cells (Palorini et al., 2013). More recently, biguanides have been 
recognized as a new class of CI inhibitors. These antihyperglycemic agents prevent ubiquinone 
reduction in a non-competitive manner, thereby stimulating ROS production (Bridges et al., 2014). 
Metformin is the most-known biguanide as it is the first line medication for the treatment of diabetes 
mellitus. Interestingly, clinical studies revealed a potential anti-neoplastic effect of the drug, the 
therapies being associated with lower risk for patient to develop cancer (Becker et al., 2014; Evans 
et al., 2005). However, these effects are still debated and warrant more investigation (Farmer et al., 
2016). Notwithstanding this, following the great surge of interest in biguanides, several in vitro and 
in vivo studies have been conducted and have provided a body of evidence for metformin-mediated 
anti-neoplastic effects (Andrzejewski et al., 2014; Wheaton et al., 2014). Upon glucose starvation, 
cancer cells were found to be more sensitive to biguanides-mediated inhibition of CI (Birsoy et al., 
2014). Accordingly, metformin, in combination with the glycolysis inhibitor 2-deoxyglucose, has 
been shown to induce cell death in vitro, AMPK activation, and it decreased the growth of several 
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xenografts models (Cheong et al., 2011). Metformin has also been shown to inhibit mitochondrial-
dependent biosynthetic processes in cancer cells (Griss et al., 2015).  
 
 
Table 1: Respiratory complex I inhibitors used as anticancer molecules.  
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Furthermore, both metformin and phenformin may synergize BRAF inhibitors to most effectively 
decrease the proliferation of BRAF-mutated melanoma cell lines (Niehr et al., 2011; Yuan et al., 
2013b). Similarly, combination of metformin and the chemotherapeutic agent doxorubicin induce 
cancer cell death more efficiently than either drug alone and prevent tumor relapse in vivo (Hirsch et 
al., 2009).  
Therefore, metformin, in combination with anti-proliferative or anti-glycolytic drugs, may be an 
effective adjuvant anti-cancer therapeutic. Nevertheless, it is important to note that beside CI 
inhibition, several other signalling pathways may be responsible for the anti-tumorigenic effects 
induced by metformin, which displays only very low specificity for the respiratory complex (Bridges 
et al., 2014; Lei et al., 2017).  
Many other pharmacological compounds have been recently developed (Table 1). Another anti-
diabetic drug, Canagliflozin, has also been studied as anticancer agent. Canagliflozin has been shown 
to inhibit complex I, to decrease glucose uptake and ATP production, and to activate AMPK in 
prostate and lung cancer cells. Treatment with this drug decreased cells proliferation and 
clonogenicity in vitro (Villani et al., 2016). On another hand, BAY-87-2243 has been shown to 
decrease mitochondrial oxygen consumption, to increase ROS generation, to reduce ATP production 
and to activate AMPK, and this was associated to a reduction of cancer cell survival in vitro. 
Furthermore, the molecule decreased hypoxia and HIF1 activation in melanoma mouse xenografts 
and sensitized them to radiation therapy (Helbig et al., 2014; Schöckel et al., 2015). Similarly, 
AG311, a compound that has been shown to exert anticancer and anti-metastatic activity, inhibits 
complex I and thereby oxygen consumption and HIF1 activation (Bastian et al., 2017). Isoflavonoids 
are instead mild CI and CIII inhibitors but induce the destabilization of the OXPHOS complexes upon 
long term treatment. In particular, the synthetic isoflavan analogue ME-344 induce cell death and 
inhibit tumor proliferation and metastasis (Lim et al., 2015). Finally, JCI-20679 is an additional CI 
inhibitor that has been shown to inhibit cancer cell growth (Akatsuka et al., 2016).  
Development of CI inhibitors is thus in full swing in cancer research. Nonetheless, given the adverse 
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effects and the wide-spread response of the compounds, the mechanisms underlying the anti-
tumorigenic effects observed upon suppression of CI activity are still poorly understood and ought to 
be further dissected. For that purpose, an accurate and specific targeting of the multisubunit complex 
in cancer cells is required. 
 
Zinc finger nucleases technology as a useful tool for CI activity suppression  
 
Gene inactivation is a powerful way to provide conclusive information on its function. This approach 
is referred to as reverse genetics and can be summarize as a “from gene to phenotype” approach, in 
contrast with “forward genetic”, which aims at identifying the genetic cause of a specific phenotype. 
For instance, the latter approach has demonstrated that the oncocytic phenotype may likely arise from 
severe CI mutations. Knocking out CI in cancer cells would instead provide important insights on the 
role of this enzymatic complex in cancer progression, via phenotypic analysis. The reverse genetics 
strategy has first been possible with the emergence of recombinant DNA (rDNA) technology in the 
70’s, and has enabled remarkable advances in biological and medical sciences (Capecchi, 2005). Yet, 
this technique was far from being affordable for any research laboratories. rDNA technology showed 
low efficiency and required the development of time-consuming selection/screening strategies. 
Moreover, the occurrence of adverse mutagenic effects was common (Gaj et al., 2013).  
In the past 15 years, the emergence of the zinc finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs) and CRISPR/Cas technologies has sparked a second revolution that has 
further extended the frontiers of biological research. They all consist in non-specific engineered 
nucleases that are fused to investigator-designed DNA binding domains that can virtually recognize 
any sequence in any genome. These new genome-editing tools were rapidly assimilated and utilized 
by the whole research community, by means of their ever-higher simplicity and efficiency in inducing 
site-directed mutagenesis. 
The ZFNs were the first engineered molecular scissors that hit the scene (Figure 11). Zinc finger 
proteins (ZFPs) are the most common DNA binding domains found in eukaryotes, being involved in 
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many functions such as transcription processes. One zinc finger domain can recognize three DNA 
base pairs (bps) via an α-helix (Figure 11).  
 
Figure 11: Structure and design of zinc finger nucleases 
One zinc finger protein (ZFP) can recognize 3 DNA base pairs and several ZFPs are used to 
specifically recognize a DNA sequence in the genome. ZFPs are fused to FokI restriction enzymes. 
The latter can catalyse a DNA double strand break (DSB) only when they dimerize. DSBs can be 
repaired by Non-Homologous End Joining (NHEJ) or Homologous Recombination (HR). NHEJ is 
utilized to insert mutations that may prevent the production of the functional protein. HR is utilized 
when a specific sequence should be inserted. 
  
Three clustered domains are frequently found associated and enable the zinc finger proteins to 
recognize a set of 9 bps, with different levels of selectivity. Conversely, engineered ZFPs have been 
designed to bind up to 18 bps of a DNA sequence, by means of 6 zinc finger domains, thereby 
conferring a specificity within 68 billion bps of DNA (Gaj et al., 2013). ZFPs are fused with the 
nuclease domain of the Fok1 restriction enzyme. The latter was of great interest since it must dimerize 
to cleave DNA. Hence a double strand break (DSB) can be induced only upon two adjacent and 
independent binding events, with correct orientation and appropriate spicing to allow the formation 
35 
of the dimer (Urnov et al., 2010). These conditions greatly favour ZFNs site-specificity together with 
reducing off-target effects.  
Once a DSB has been introduced at the locus of interest, cells can repair it via homology-directed 
repair (HDR) or non-homologous end joining (NHEJ) pathway. HDR canonically utilizes the 
homologous sequence of a paired chromosome as a template to correctly repair the harmful break. 
Taking advantage of this, the DNA repair processes may therefore be driven by the addition of a user-
specified donor DNA, which is usually aimed at correcting a mutation or inserting a new gene. 
Conversely, the NHEJ pathway rapidly ligates the two broken ends, a process which occasionally 
introduces small insertions/deletions. The latter is therefore exploited as a strategy towards gene 
disruption, as the mutations may introduce a frameshift that prevents the production of the protein.  
Nowadays, ZFN technology has been largely replaced by the CRIPR/cas system, far more attractive 
for its specificity, cost and ease of use.  
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AIMS 
Prior to the present work, ours and other groups have shown that severe CI dysfunctions can be 
disadvantageous to tumor growth by negatively impacting on tumors metabolic adaptation to 
hypoxia, therefore disclosing this enzyme as a potential target for cancer therapy. These studies were 
performed on oncocytomas samples harbouring CI-disruptive mtDNA mutations, and on cancer 
cybrid models, where the load of the latter mutations could be monitored. The pseudonormoxic 
feature of CI-deficient cancer cells evidenced a two-way relationship between mitochondria and the 
transcription factor HIF1a, whose stabilization requires CI activity. However, the mechanism 
underlying HIF1a destabilization in CI-deficient cancer cells remained to be demonstrated. Further, 
whether the latter was the primary cause of the low tumorigenic profile observed was still unclear.  
This study aims at mimicking the effects of severe CI-disruptive mtDNA mutations in cancer cells. 
For this purpose, the ZFN technology is utilized to create stable cancer cell models lacking CI. The 
former approach will permit to dissect the biochemical and metabolic profiles of CI-deficient cancer 
cells, together with identifying the molecular actors that drive HIF1a destabilization. Moreover, the 
genetic stability provided by such a tool prevents any genetic drift otherwise triggered when studying 
mtDNA mutations. In this light, in vivo studies will provide important insights on the effect of CI 
irreversible loss on tumor growth and progression. A proof of concept study will further confirm the 
results obtained by re-inserting NDUFS3 in CI-deficient cancer cells. Conversely, the effect of CI 
loss during tumor progression will be investigated by suppressing NDUFS3 expression while CI-
competent xenografts have already reached advanced development stage.  
Lastly, this work is expected to establish the backbone of a more complex investigation that will help 
to further confirm the pivotal role of HIF1a loss in preventing tumor growth, while discriminating 
the relative significance of CI disruption in carcinogenesis and cancer progression.   
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EXPERIMENTAL PROCEDURES 
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Genome editing 
 
Plasmids containing cDNA of NDUFS3-targeted zinc finger endonucleases were purchased from 
Sigma-Aldrich and used following the manufacturer’s instructions. The plasmids were purified and 
transcribed in vitro using MessageMax caping kit (Cell Script), Poly adenylation kit (Epicentre) and 
purified using MegaClear kit (Life Technologies). The pool of zinc finger endonucleases mRNAs 
(2.5ug each) was transfected using Transit-mRNA transfection kit (Mirus) into 70% confluent cells. 
Cells were split 48 hours after transfection and DNA was extracted using Mammalian Genomic DNA 
Miniprep Kit (Sigma-Aldrich). Non-homologous repair efficiency was evaluated by Fluorescent PCR 
using KAPA2G taq polymerase (Kapa Biosystems) with 58°C annealing and primers forward 
CTGCCACAAGGAGCTAGGAC and reverse GCACAGGGAGATAAAAGGCA. Clonal selection 
was performed in order to identify the cells with frameshift NDFUS3 mutations (Figure 12). Selection 
media used for the growth in 96-well plates was composed of DMEM High glucose supplemented as 
described below with subsequent modifications: 20% FBS, L-Tryptophan (32mg/l, Sigma-Aldrich) 
and Nicotinamide (8mg/l, Sigma-Aldrich). Genotyping was performed after DNA extraction from 
96-well plates using 8µl of Lysis Solution (Sigma-Aldrich) and 80µl of Neutralization Buffer (Sigma-
Aldrich) per sample. Heterozygous clones were first expanded and a subsequent second transfection 
with NDUFS3 zinc finger pool was performed as described above. This step led to the selection of 
homozygous frameshift NDUFS3 mutants and homozygous wild-type (WT) revertants. The latter 
were used as controls in all experiments described here. Three clones per genotype were obtained for 
143B and two for HCT116 cells. NDUFS3 genotype was confirmed by Sanger sequencing using 
KAPA2G taq polymerase (Kapa Biosystems) and Big Dye protocol (Life Technologies). 
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Figure 12: Illustration of the cell selection procedure 
Blue pics are F-PCR results for a selected population of cells. The horizontal position of the pic is 
defined by the length of the PCR-amplicon while its height is proportional to the number of amplicons 
at this specific length, hence representative of the number of alleles bearing one, two or no mutation 
in the given population of cells analysed. Briefly, after a first transcription with the ZFNs, a 
population of cells bearing potential interesting mutations is obtained (i.e. 5 insertions). Single cells 
are distributed in each well of three 96 well plates.  F-PCR on the colonies obtained allowed to isolate 
a population of cancer cells whose one NDUFS3 allele presented with 5 insertions. These cells were 
transfected again with the ZFNs. A second screening has led to the isolation of cells with two alleles 
with frameshift mutations and cells that have reverted the mutations and are therefore NDUFS3 wild 
type.  
 
Cell culture 
 
Osteosarcoma 143B Tk- cells and colorectal cancer HCT116 cells were cultivated in Dulbecco’s 
modified Eagle medium (DMEM) High Glucose (Euroclone), supplemented with 10% fetal bovine 
serum (Euroclone), L-glutamine (2mM, Euroclone), penicillin/streptomycin (Euroclone) and uridine 
(50µg/ml, Sigma-Aldrich), in an incubator with a humidified atmosphere at 5% CO2 and 37°C. Cells 
were replaced by a fresh batch upon 15 passages and mycoplasma testing was performed before 
disposal and after each thawing (approximately every two months). Experiments in hypoxia were 
performed inside the Invivo2 300 (Baker Ruskinn) chamber, set up at 5%CO2, 37°C and 1% O2. 
Where indicated, cells were incubated for 5 hours with dimethyloxalylglycine [DMOG (1mM), 
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Sigma-Aldrich] or MG132 (10µM, Sigma-Aldrich) and 1 hour with pimonidazole (100µM, 
Hypoxiprobe) at indicated concentrations. Cell origin was authenticated using AMPFISTRIdentifiler 
kit (Applied Biosystems). 
 
SDS-PAGE and Western blot analysis 
 
Whole lysates of cultured cells and freshly snap frozen xenograft samples were prepared in RIPA 
buffer [TrisHCl pH7.4 (50mM), NaCl (150mM), SDS (1%), Triton (1%), EDTA pH7.6 (1mM)] 
supplemented with protease inhibitors (Roche) and quantified by Lowry protein assay (Biorad). 
Samples were separated by SDS-PAGE and transferred to the nitrocellulose membrane using Turbo-
pack system (Biorad). The membranes were blocked 30 minutes at 37°C and incubated with primary 
antibodies using following dilutions/conditions: anti-NDUFS3 (Abcam) 1:1000/1 hour at room 
temperature (RT); anti-HIF1a (GeneTex) 1:2000/1 hour at RT; anti-Vinculin (Sigma-Aldrich) 
1:10000/1-hour at RT; anti-pimonidazole (Hydroxyprobe) 1:3000/2 hours at 37°C; anti-HIF2a 
(Novus Biologicals) 1:1000/1 hour at RT, anti-HIF1a-OH (Cell Signalling) 1:500/O/N at 4°C. 
Washes were performed 4 x 5 minutes using TBS-Tween [0.1% Tween 20 (Sigma-Aldrich) in Tris 
Buffered Saline] and incubation with secondary antibodies (Jackson ImmunoResearch Laboratories), 
diluted 1:20000 in TBS-Tween, was performed for 30 minutes at RT. Developing was performed by 
using Clarity Western ECL Substrate (Biorad) and exposing with ChemiDoc XRS+ (Biorad). For 
anti-HIF1a-OH, anti-phospho-AKT and anti-phospho-ERK antibodies Western Breeze system (Life 
Technologies) was used in terms of secondary antibody and developing solutions, following the 
manufacturer’s instructions. 
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Mitochondrial isolation 
 
Crude mitochondria were obtained by 15x106 cells. Cells were suspended in cold isolation buffer 
containing 200 mM D-Mannitol, 70 mM Sucrose, 1 mM EGTA, 10 mM HEPES, pH 7.6, with 
protease inhibitor cocktail (Roche) and mechanically homogenized with 50 strokes using a glass-
teflon potter in melting ice. Unbroken cells and nuclei were centrifuged at 3000 rpm for 10 minutes 
at 4°C, and the supernatant, containing mitochondria, was centrifuged at 13000 rpm for 20 minutes 
at 4°C. The mitochondrial pellet was suspended with cold isolation buffer and stored at -80°C. Protein 
content was quantified according to Bradford’s protocol (Bradford, 1976). 
Membrane fractions enriched of mitochondrial proteins (mitoplasts) were isolated from cell pellets 
(10x106 cells) using digitonin (final concentration 50 µg/mL). Digitonin binds to membrane 
cholesterol, destabilizing and solubilizing the cellular membranes. The inner membrane, unlike the 
outer membrane, is almost devoid of cholesterol, therefore digitonin solubilizes cellular membranes, 
except the inner membrane, which remaining intact can be isolated. Briefly, cells were centrifuged 
and pellet suspended at a concentration of 10x106 cells/mL with cold PBS (154 mM NaCl, 1 mM 
KH2PO4, 3 mM Na2HPO4), and after addition of digitonin, incubated on ice for 1 minute. Cold PBS 
was then added to 2.5- fold dilute the suspension volume, thus interrupting cell permeabilization. The 
digitonin treatment was repeated until at least 90% of the cells were permeabilized, as detected at the 
microscope by Trypan blue cell permeabilization. Cells were then centrifuged at 13000 rpm for 15 
minutes at 4°C and the pellet was stored at -80°C. Protein content was quantified according to 
Bradford (Bradford, 1976). 
 
CN-PAGE 
 
Complex I was separated through Clear Native PAGE (CN-PAGE) (Wittig et al., 2006). Cells were 
resuspended at 107 cells/ml in PBS, permeabilized with 50 µg/ml digitonin, centrifuged at 13000 rpm 
for 10 minutes and the mitochondrial pellet was stored at -80°C. The day after it was resuspended in 
mitochondrial buffer (750 mM 6-aminocaproic acid, ACA; 50 mM BisTris, pH 7.0), the proteins 
44 
quantified and DDM (n-Dodecyl β-D-maltoside) added at 2,5-fold the protein quantity. Afterwards 
samples were incubated in ice for 10 minutes and then centrifuged at 13000 rpm for 15 minutes at 
4°C. The supernatant containing the mitochondrial proteins was then recovered and proteins 
quantified. The supernatant collected was diluted in CN-Sample Buffer (0.1% Red Ponceaux and 
50% Glycerol). 50 µg of mitochondrial protein samples were loaded onto a native gel constituted by 
a gradient of polyacrylamide from 4% to 12%, made with a gradient building machinery and a 
peristaltic pump (Delta-Pump). Running gels were prepared adding to established acrylamide 
concentrations 25 mM Imidazole, 0.5 M ACA, pH 7, 0.02% APS and 0.02% TEMED; 10% glycerol 
was added to the gradient with higher concentrations. Stacking gel contained 4% acrylamide. Anode 
buffer and Cathode buffer were used for CN-PAGE (50 mM Tricine, 7.5 mM Imidazole, 0.02% 
DDM, 0.05% NaDOC pH 7). The electrophoresis was carried at 80V. After electrophoresis, gels were 
submerged for 15 minutes at room temperature, in the dark, in a solution containing 2 mM Tris-HCl, 
0.5% 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 0.02% NADH. The 
CI appeared as a black band due to the reduction of MTT to tetrazolium salts by NADH oxidation 
through CI. 
Measurement of complex-specific ATP synthesis 
 
The rate of mitochondrial ATP synthesis driven by CI, CII and CIII was measured in digitonin-
permeabilized cells as previously described (Ghelli et al., 2013). Briefly, after trypsinization, cells 
(10×106/ml) were suspended in a buffer containing 150mM KCl, 25mM Tris–HCl, 2mM EDTA 
(ethylenediaminetetraacetic acid), 0.1% bovine serum albumin, 10mM potassium phosphate, 0.1mM 
MgCl2, pH 7.4, kept at room temperature for 15 minutes, then incubated with 50µg/ml digitonin until 
90-95% of cells were positive to Trypan Blue staining. Aliquots of 3×105 permeabilized cells were 
incubated in the same buffer in the presence of the adenylate kinase inhibitor P1,P5-di(adenosine-5′) 
pentaphosphate (0.1mM) and OXPHOS complexes substrates. Chemiluminescence was determined 
as a function of time with Sirius L Tube luminometer (Titertek-Berthold, Pforzheim, Germany). The 
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chemiluminescence signal was calibrated with an internal ATP standard after the addition of 10µM 
oligomycin. The rates of the ATP synthesis were normalized to protein content and citrate synthase 
(CS) activity (Trounce et al., 1996). 
 
Measurement of complexes activity 
 
Crude mitochondria were used to measure redox activities with a UV-Vis spectrophotometer (V550 
Jasco). For CI and CII activity, spectrophotometric assay was performed at 600nm wavelength, at 
37°C and under continuous stirring, by following the 2,6-Dichlorophenolindophenol (DCIP) 
reduction. Kinetic was calculated using the DCIP molar extinction coefficient (19.1 mM-1cm-1). The 
CIII and CIV activities were analyzed with a dual-wavelength spectrophotometer (540 nm-550 nm) 
at 37 °C and under stirring, following the reduction or oxidation of cytochrome c (molar extinction 
coefficient 19.1 mM-1cm-1). 
25 µg of crude mitochondria were used in each assay. The specific activity was measured after 
subtraction of non-specific activity conducted in a separate assay, adding the specific complex 
inhibitors at the beginning of the reaction (CI: 1 µM Rotenone; CII: 5 mM Malonate; CIII: 1 µM 
Antimycin A; CIV: 300 µM KCN) (Carossa et al., 2014; Ghelli et al., 2013). For details about reaction 
components see Table M1. 
The activity of CS was evaluated in mitochondria suspended in a buffer containing 125 mM Tris-
HCl, 0.1% Triton X-100, 100 µM DTNB (ε= 13.6 mM-1), 300 µM Acetyl-CoA, pH 8. The reaction 
was started by addition of 500 µM Oxaloacetate (Trounce et al., 1996) and measured at 412 nm at 
30°C with UV-Vis spectrophotometer (V550 Jasco).  
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Table M1: Reaction component for OXPHOS complexes activity measurements 
 
Oxygen consumption rate 
 
Oxygen Consumption Rate (OCR) was measured using the Seahorse XFe24 Extracellular Flux 
Analyzer (Seahorse Bioscience) as previously described (Iommarini et al., 2013). Cells were seeded 
(3x104 cells/well) into XFe24 cell culture plate and allowed to attach for 24 hours. Cell culture media 
was replaced with XF media (Seahorse Bioscience). OCR was measured over a 3 minutes period, 
followed by 3 minutes mixing and re-oxygenation of the media. For Mito Stress Test, complete 
growth medium was replaced with 670µl of unbuffered XF media supplemented with 10mM glucose 
pH 7.4 pre-warmed at 37°C. Cells were incubated at 37°C for 30 minutes to allow temperature and 
pH equilibration. After an OCR baseline measurement, 70µl of oligomycin, carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP), and rotenone plus antimycin A were sequentially added 
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to each well to reach final concentrations of 1µM oligomycin, 0.25µM FCCP, and 1µM rotenone and 
antimycin A. Three measurements of OCR were obtained following injection of each drug and drug 
concentrations optimized on cell lines prior to experiments. At the end of each experiment, the 
medium was removed and SRB assay was performed to determine the amount of total cell proteins 
as described above. OCR was normalized to total protein levels (SRB protein assay, see below) in 
each well. Each cell line was represented in 5 wells per experiment (n = 3 replicate experiments). 
Data are expressed as pmoles of O2 per minute (OCR) normalized on SRB absorbance. 
 
Cell viability 
 
Cell viability was measured by the Sulforhodamine B (SRB) assay (Sigma-Aldrich) and by cell 
counting after Trypan Blue (Sigma-Aldrich) staining. Cells were seeded in 24-well plates (7.5x103 
cells/well for 143B and 10x103 cells/well for HCT116) in complete medium. For additional 
conditions, 24 hours post-seeding cells were washed twice in PBS and incubated in indicated media. 
Evaluation of growth in galactose condition was performed as described in (Ghelli et al., 2003). 
Briefly, at the end of incubation time, cells were fixed with 50% trichloroacetic acid for 1 hour at 
4°C, washed 5 times with H2O and finally dried for 1 hour at room temperature. Cells were then 
stained with SRB 0.4% diluted in 1% acetic acid for 1 hour at room temperature, washed 4 times with 
1% acetic acid, and disrupted with 10 mM Tris-HCl pH 9.8. The absorbance of SRB was detected 
with Victor3 plate reader (Perkin Elmer) at the wavelength of 560 nm. 
 
Metabolomics 
 
Metabolite concentrations were measured with Carcinoscope analysis [Human Metabolome 
Technologies (HMT)] which uses capillary electrophoresis coupled to time of flight/triple quadrupole 
mass spectrometry and provides absolute quantification of 116 targeted metabolites. Metabolites 
were extracted using 100% methanol supplemented with 550µl of Internal Standard Solution 
provided by HMT from 2-5 million cells seeded on 90mm plate. The metabolite concentrations were 
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normalized to the number of viable cells. For mass isotopomer analysis, cells were incubated for 3 
hours either with DMEM High glucose (Euroclone) supplemented with [13U] labelled glutamine 
(2mM) or with DMEM (Life Technologies) supplemented with [13C] labelled glucose (25mM) and 
sodium pyruvate (110mg/l, Sigma-Aldrich). Nutrients labelled with 13C were purchased from 
Cambridge Isotope Laboratories. Metabolite extraction was performed as described above and the 
isotopomer distribution was evaluated with F-Scope analysis (HMT) that enables determination of 
metabolic flux by measuring absolute concentrations and tracer-labelled fractions of 54 targeted 
metabolites. 
 
ATP measurements 
 
Aliquots of 1.5 × 106 cells were washed, resuspended in 1 ml of ice-cold PBS and extracted for ATP 
determination. Briefly, cell suspension was treated with 1M perchloric acid (PCA), immediately 
cooled on ice and centrifuged at 48°C to remove insoluble material. PCA was neutralized with 
potassium hydroxide and samples were centrifuged immediately before injection. The supernatant 
(100 ml) was injected on C18 column. ATP was extracted and detected as described by Jones (Jones, 
1981) on a Kinetex reversed phase C18 column (250 × 4.6 mM, 5mm; Phenomenex, CA, USA), with 
a two pump Waters 510 system equipped with a variable volume injector. Absorbance at 260 nm was 
monitored by a photodiode array detector (Waters 996). ATP peak was identified by comparison of 
its retention time with those of standards and confirmed by co-elution with standards. The 
quantification was obtained by peak area measurement compared with standard curves and data were 
normalized for protein content, determined by Bradford assay (Bradford, 1976). 
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Glucose uptake 
 
Glucose consumption was determined by using the Glucose (GO) Assay Kit (Sigma-Aldrich) scaling 
down the manufacturer protocol to a final volume of 1 ml. Briefly, cells were seeded in 6-well plates 
(1 × 105 cells/well) in high glucose medium. After 48 hours, cells were washed in PBS and incubated 
with DMEM-high glucose without phenol red. Aliquots of 100 ml of medium were taken at time 0 
and after 24 hours of incubation and 3 ml of samples were used to determine the glucose 
concentration, by the enzymatic reaction of glucose oxidase coupled to peroxidase-mediated 
oxidation of reduced o-Dianisidine (l 1⁄4 540 nm, 30 min, 378C). The data obtained were normalized 
on cell number. 
 
Lactate production 
 
Cells were seeded in 6-well plates (3x105 cells/well) in 2ml of high-glucose medium. After 24 hours 
and 48 hours aliquots of medium were collected and deproteinated with 6% PCA, vortexed and 
incubated in ice for 1 minute. Samples were centrifuged at 13000rpm at 4°C for 2 minutes and the 
lactate concentration in supernatants was determined by measuring NADH (λ=340nm; ε=6.22mM-1 
cm-1) production in a buffer containing 320mM glycine, 320mM hydrazine, 2.4mM NAD+ and 
2U/mL L-lactic dehydrogenase (Sigma-Aldrich) after 30 minutes of reaction at 37°C. Data were 
expressed as pmoles of lactate produced by 1000 cells. 
 
Clonogenic assay 
 
The ability of cells to maintain survival and mitotic ability was determined by seeding cell 
suspensions (500 cells per 32-mm dish) in growth medium and incubated at 37°C in a humidified 5% 
CO2 atmosphere. Colonies were fixed after 10 and 14 days, for 143B and HCT116, respectively, 
using 50% Trichloracetic acid (Sigma-Aldrich), colored with SRB (Sigma-Aldrich) and destained 
with 1% acetic acid (Sigma-Aldrich). Images were acquired using ChemiDoc XRS+ (Biorad) and 
counted using ImageJ (Collins, 2007). 
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Anchorage-independent growth assay 
 
Anchorage-independent cell growth was determined in 0.33% agarose with a 0.5% agarose underlay. 
Cell suspensions (1x104 cells per 32-mm dish) were plated in semisolid medium (growth medium 
plus agar 0.33%) and incubated at 37°C in a humidified 5% CO2 atmosphere (Iommarini et al., 2013). 
Colonies were counted after 10 days at a magnification of 10× with an inverted microscope (Nikon 
Diaphot, Nikon Instruments). Images were acquired with Gel Logic 1500 molecular imaging 
apparatus (Kodak). 
 
2D-migration assay 
 
Cells were cultured to confluence in 6-well plates. Under aseptical conditions a thin wound was 
induced by scratching with a 200µl pipette tip and detached cells were rinsed with PBS. Using a 
phase contrast set up and a 10× magnification wound healing was monitored to identify invading cells 
at different time points. For quantitative evaluation, images of 20 sequential open wound areas were 
acquired using digital photo camera mounted on the microscope and analyzed with T-scratch software 
(CSElab). The capacity to invade was expressed as the percentage of open wound area. 
 
In vivo studies 
 
For in vivo studies, nu/nu mice (CD-1® Nude Mouse Crl:CD1-Foxn1n) were used, purchased from 
Charles River Laboratories. The animals were treated according to institutional guidelines and 
regulations and experiments were performed following the protocol approved by the SALK ethical 
committee. Five to six weeks old female mice were subcutaneously inoculated with a 200µl 
suspension of 15x106 cells in serum free medium and matrigel (BD Bioscience, Franklin Lakes, NJ, 
USA) in the right flank of the animal. Xenograft size was measured with a sliding caliper twice a 
week, according to the formula (width x height x length/2). Mice were sacrificed either 
simultaneously, when the first xenograft reached 3cm3, or consecutively, when each animal reached 
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xenograft volume of 3cm3 (or met the termination criteria). For the experiments with doxycycline 
(Dox), A total of 3% sucrose with or without 1mg.ml-1 Dox was added into the drinking water of 
mice once each tumor with the inducible lentiviral system has exceeded 450mm3, and the water was 
changed twice a week. Prior to the sacrifice (3 hours before) all animals were injected 
intraperitoneally with pimonidazole (60 mg/kg, (Hypoxyprobe) diluted in saline solution. The 
xenografts were snap frozen for protein, DNA and RNA extraction and formalin fixed for IHC 
analysis. 
Measurement of H2O2 production 
 
Production of H2O2 was measured in cells grown in complete high glucose medium. 100,000 cells 
were treated with 2,7-dichlorodihydrofluorescein diacetate (H2DCFDA) (Life Technologies) to a 
final concentration of 100 mM, and incubated at 37°C for 30 minutes. The cells were then collected 
and the reaction was stopped by placing them in an ice bath for 5 minutes. The cells were disrupted 
by treatment with Triton X-100 (2%) and centrifuged at 2,500g for 20 minutes at 4°C. The supernatant 
was used to measure fluorescence emission (excitation, 485 nm; emission, 535 nm) in a multilabel 
counter Victor3 (Perkin Elmer). The amount of H2O2 produced was calculated by using a standard 
curve of 2,7-DCFH2 in which 1 mM of 2,7-DCFH2 represented 1 mM of H2O2.  
Immunohistochemical staining 
 
For immunohistochemical staining, the following antibodies were used: rabbit monoclonal anti-
complex I subunit NDUFS3 (1:200; Abcam), rabbit polyclonal anti- HIF1a (1:350; Sigma-Aldrich), 
mouse monoclonal anti- pimonidazole (1:400; Hypoxyprobe), rabbit monoclonal anti-CD-31 (1:50; 
Abcam), mouse monoclonal anti-human ki67 (1/100Dako). All antibodies were diluted in Dako 
antibody diluent with background reducing components (Dako).  
Tissue sections (4mm) were deparaffinised by three changes of xylene, rehydrated in three changes 
of absolute 2-propanol followed by heat-induced epitope retrieval in TE-T buffer (10 mM Tris pH 
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9.0, 1 mM EDTA, 0.05% Tween 20) for 40 minutes at 95°C and 20 min at room temperature. Sections 
were equilibrated with phosphate-buffered saline containing 0.5% Tween 20 (PBS-T pH 7.4). 
Staining was carried out using the Envision Detection System (Dako) according to the manufacturer’s 
instructions followed by visualisation with diaminobenzidine (DAB) for 10 minutes. Slides were 
counterstained with haematoxylin.  
Masson’s Trichrome  
 
Tissue sections (4mm) were deparaffinised by two changes of xylene and then dehydrated by two 
changes of industrial methylated spirit and subsequently washed in tap water. Nuclei were stained in 
Weigert’s Iron Haematoxylin in 15minutes. Cytoplasms were stainined in red using Ponceau 2R-
/acid Fuchsin Solution for 4 minutes. Collagen fibres are stained in Aniline Blue in 1% Acetic Acid 
for 5 minutes, after being decolourised by 1% Aqueous Phosphomolybdic Acid. For details about the 
solutions utilized see Table M2. 
Table M2: Preparation of solutions for Masson’s Trichrome staining 
Electron microscopy 
 
Directly after xenograft removals, small sections (≤ 5mm3) were immersed in cacodylate buffer 0,1M 
with 2.5% glutaraldehyde and 4% paraformaldehyde and stored during 24 hours at 4°C. After 24 
hours, this fixation solution is replaced by a solution of cacodylate buffer 0,1M without 
glutaraldehyde and paraformaldehyde. Within 3 weeks after samples collection, sections (1 µm) were 
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stained with 1% toluidine blue for morphology control and electron microscopy area selection. Thin 
sections were observed with JEM-1011 Transmission Electron Microscope (JEOL Ltd).  
Generation of NDUFS3 inducible knock-out cells  
 
To create a stable inducible transgenic cell line re-expressing NDUFS3, the Retro-X Tet-Off 
Advanced Inducible Expression Systems (Clonetech) was utilized following the manufacturer’s 
instructions. Two separate infections were performed with the following vectors: pRetro-X Tet-Off 
Advanced, which constitutively expresses the transactivator tTA-Advanced, controlled by the 
tetracycline analogous Dox, and the pRetroX-Tight-Pur in which wild-type NDUFS3 cDNA 
sequence was cloned, therefore called pRetroX-Tight-Pur-NDUFS3, which expresses NDUFS3 
under the control of an inducible promoter recognized by tTA-Advanced. NDUFS3 cDNA has been 
obtained through a retrotranscription reaction after that RNA was extracted from human blood using 
the high capacity cDNA retrotranscription kit (Life Technologies) and primers containing the 
restrictions sites NotI and EcoRI.  
First, the gene has been inserted in the pGEM®-T Easy Vector (Promega), which was utilized to 
transform E. cloni 10G Chemically Competent DUOs cells (Lucigen). Colonies have then been 
selected through a white/blue screening. After DNA extraction from a positive clone, the integrity of 
the NDUFS3 gene and the presence of the regulatory element requested for its expression were 
confirmed by Sanger sequencing using KAPA2G taq polymerase (Kapa Biosystems) and Big Dye 
protocol (Life Technologies).  
Secondly, the plasmid pGEM®-T/NDUFS3 has been digested with the NotI and EcoRI digestion 
enzymes and the cDNA was cloned inside the pRetroX-Tight-Pur. This vector has been used to 
transform the E.coli 10G Chemically Competent DUOs cells. Colonies were selected with ampicillin 
and the screening has been performed  
The pRetroX-Tet-Off Advanced vector was transduced in 143B NDUFS3-/- cells. The selection of 
cells that have integrated the plasmid was performed using G418 (400µg/ml, Sigma). Cells were then 
maintained in a medium containing G418 (100µg/ml). Single cell cloning of selected cells was then 
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performed. Cells with optimal tTA-Advanced activity were identified by measuring luciferase 
activity as it follows. The pRetroX-Tight-Pur-LucControl Vector was transiently transfected using 
X-treme GENE HP DNA Transfection Reagent (Roche) into cells (8.104) seeded in 6-well plates 
incubated with a medium containing Clonetech tetracycline-free FBS (Clonetech). Each clone was 
then treated with or without Dox (concentration 100ng/ml, Geneticin, Life technologies). After 48 
hours, cells were harvested and processed with the Luciferase assay kit (Dual-Luciferase(R) Reporter 
Assay System, Promega) protocol. The luciferase activity was analyzed by Luminometer (Titertek-
Berthold). As expected, the intensity was high in absence of Dox (cDox) and low in cells cultivated 
with 100ng/ml of Dox (+Dox) in the medium. Two clones with the lowest + Dox luciferase activity 
were pooled together and the second viral transduction was performed as described above, using the 
pRetroX-Tight-Pur-NDUFS3 Vector. The selection of cells that have incorporated the plasmid was 
performed using 0.5µg/ml of puromycin (Gibco). Cells were then cultured in a medium containing 
puromycin 0.25 µg/ml. Single cell cloning of selected cells was performed to select clones without 
NDUFS3 in a +Dox medium, while able to express NDUFS3 in a –Dox medium. Four of the selected 
clones were pooled to obtain 143B NDUFS3-/- ind. 
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Generation and biochemical characterization of NDUFS3-/- cancer cells.  
 
With the aim of generating CI-deficient cell models, the knock-out of NDUFS3 (NDUFS3-/-) was 
induced in the osteosarcoma cell line 143B and the intestinal carcinoma cell line HCT116 by using 
the ZFN technology. After cells transfection with the ZFNs, single cell cloning has allowed the 
isolation of individual cells with potential genotypes of interest. Fluorescent PCR (F-PCR) and 
Sanger sequencing performed on the population of cells obtained have permitted to identify and to 
select the clones containing frameshift mutations at the 5’ end of one or the two alleles of the 
NDUFS3 gene (NDUFS3-/-), which are likely to prevent the proper translation of the mRNA (Figure 
12). Western Blot analysis on three selected cell lines confirmed the absence of the protein in 
NDUFS3-/- clones (Figure 13 upper panel). Importantly, three NDUFS3+/+ cells are clones having 
reversed the mutations induced and therefore they express NDUFS3 (Figure 13 upper panel). Given 
the fact that the latter have followed the same selection processes than NDUFS3-/- cells, they 
represented appropriate control for all the further analysis, and they were used as such.  
 
 
Figure 13: NDUFS3-/- clones lack NDUFS3 and display a significant reduction of CI activity 
SDS page followed by western blot analysis on three 143B clones and two HCTT116 clones for each 
genotype (upper panel). Clear-Native PAGE followed by CI-in gel activity on the same clones. Black 
bands appear only upon NADH oxidation by CI (lower panel). 
 
The assembly and the activity of the CI were then investigated in the different models obtained. As 
initially hypothesised, and confirming the crucial role of NDUFS3 for CI assembly, in-gel activity 
analysis showed a significant reduction of CI activity in NDUFS3-/- clones compared to their WT 
counterparts (Figure 13 lower panel). This finding was further confirmed by the measurement of ATP 
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synthesis mediated by the CI, whose values were found drastically decreased in CI-deficient clones, 
while CII and CIII showed no altered capacity to participate to ATP production (Figure 14). In line 
with the above, among all the complexes of the respiratory chain and citrate synthase, only complex 
I showed a decrease in its activity in 143B NDUFS3-/- clones (Figure 15).  
 
 
Figure 14: CI-mediated ATP synthesis is significantly reduced in 143B cells and HCT116 cells 
The ATP synthesis rate driven by complex I (pyruvate and malate) or complex II (succinate plus 
rotenone) or complex III (DBH2) was determined in isolated mitochondria by the luciferase assay 
using a luminometer. The values (nmol/min*mg protein) were normalized for CS activity. Data are 
means ± SEM of three experiments. * P<0.05; ** P<0.01 
 
 
Figure 15: Only the activity of the CI is significantly reduced in NDUFS3-/- 143B clones 
Analysis of the respiratory complexes redox activity. Measurement of CI, CII, CIII and CIV redox 
activity and CS synthase activity in crude mitochondria extracted from 143B clones. Data are means 
± SEM of three experiments. ** P<0.01. 
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Notwithstanding the fact that the rest of the respiratory chain remained unaltered, oxygen 
consumption rate measurement revealed that disruption of CI in NDUFS3-/-  cell lines was sufficient 
to abrogate mitochondrial respiration, while, contrariwise, NDUFS3+/+ cells significantly utilized the 
respiration chain (Figure 16).  
 
 
Figure 16: Loss of CI abrogates mitochondrial respiration in 143B and HCT116 clones 
Oxygen consumption rate measurement by Seahorse assay. After addition of oligomycin (O), the 
subsequent decrease of the OCR represents the respiration that served for ATP production. The 
slopes induced upon addition of FCCP (F) and then rotenone (R) and antimycin (A) permits to 
calculate the maximal capacity of cells to respire. Data are means ± SEM of three experiments. * 
P<0.05. 
 
 
Accordingly, only NDUFS3+/+ clones could grow in a glucose-free, galactose medium, which forces 
cells to rely on respiration to proliferate (Figure 17A). Quantifying ATP levels in the latter condition 
confirmed that NDUFS3-/- clones were no longer able to produce ATP though OXPHOS (Figure 
17B). 
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Figure 17: NDUFS3-/- clones do not sustain proliferation nor they maintain ATP levels when 
forced to rely on mitochondrial respiration 
(A) Time course of 143B and HCT116 clones’ viability in DMEM-galactose The SRB absorbance 
value at time zero corresponds to 100% viable cells. (B) ATP is detected by HPLC and absorbance 
is measured at 260nM. Values are normalized for cell number. Data are means ± SEM of three 
experiments. * P<0.05; ** P<0.01. 
 
In line with previous studies, HMT metabolomics revealed that the strong OXPHOS defects induced 
in 143B clones is associated with a significant reduction of aspartate levels, while the amount of the 
other amino acids remained unchanged, thus not impacting on total amino acids quantity (Figure 18). 
Nevertheless, when cultured in similar, high glucose conditions, no significant difference was found 
regarding ATP production (Figure 19A) and only CI-deficient HCT116 cells, and not 143B, displayed 
a slight reduction of viability (Figure 19B). Altogether, these data indicate that CI-deficient cells may 
use alternative metabolic routes to sustain ATP synthesis and proliferation, and that decreased 
aspartate levels is most likely not a limiting factor for the proliferation of NDUFS3-/- clones. 
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Figure 18: Aspartate levels are significantly reduced in NDUFS3-/- 143B clones 
Clones were cultured in high glucose medium and all the 20 proteinogenic amino acids, but cysteine 
(cys), could be quantified by carcinoscope analysis. Total amino acids are the summation of all the 
20 proteinogenic amino acids.  Alanine (Ala); Arginine (Arg); Asparagine (Asn); Asparate (Asp); 
Glutamine (Gln), Glutamate (Glu), Glycine (Gly); Histidine (His); Isoleucine (Ile); Leucine (Leu); 
Lysine (Lys); Methionine (Met); Phenylalanine (Phe); Proline (Pro); Serine (Ser); Threonine (Th); 
Tryptophane (Trp); Tyrosine (Tyr); Valine (Val). Data are means ± SEM of three experiments. * 
P<0.05; ** P<0.01. 
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Figure 19: NDUFS3-/- 143B and HCT116 clones sustain ATP production and cell proliferation 
in high glucose condition  
(A) Time course of 143B and HCT116 clones’ viability in DMEM-high glucose. The SRB absorbance 
value at time zero corresponds to 100% viable cells. (B) ATP is detected by HPLC and absorbance 
is measured at 260nM. Values are normalized on cell number. Data are means ± SEM of three 
experiments. * P<0.05; ** P<0.01. 
 
Interestingly, the measurement of HCT116 cells viability in galactose and glucose medium may 
indicate their higher dependence on mitochondrial respiration for proliferation than 143B cells, which 
divide much faster in high glucose condition than in galactose medium (Figures 17A and 19A). 
Upon ETC impairment, increased glycolytic machinery and reductive carboxylation of a-KG are two 
well characterized escape routes that allow cancer cells to keep meeting the metabolic requirements 
for proliferation. In line with this, a higher uptake of glucose was observed in both 143B and HCT116 
NDUFS3-/- cell lines compared to the WT (Figure 20A), together with an increase in the production 
of lactate (Figure 20B).  
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Figure 20: CI-deficient 143B and HCT116 clones consume more glucose and produce more 
lactate than CI-competent cells.  
(A) Glucose uptake and (B) Lactate production are measured by spectrophotometric assay. Data are 
means ± SEM of three experiments. * P<0.05; ** P<0.01. 
 
Furthermore, HMT analysis has revealed a higher a-KG/Citrate ratio in CI-deficient cells (Figure 
21A), which is a “trademark” of reductive carboxylation (Fendt et al., 2013). This last finding is 
further corroborated by mass isotopomer analysis that allows the tracking of glucose and glutamine 
carbons distribution into metabolic pathways. In NDUFS3-/- 143B cell lines, glucose contribution to 
citrate (m+5) is lower than in NDUFS3+/+ cells (Figure 21B), while glutamine contribution to citrate 
generation is greater in CI-deficient cell lines (Figure 21C). 
Altogether, these data demonstrate that CI loss abolishes mitochondrial respiration in 143B and 
HCT116 cells but does not induce any energetic crisis nor severe proliferation impairment. The latter 
phenomenon may be due to CI-deficient cells ability to increase glycolysis and to trigger glutamine-
dependent reductive carboxylation, when adequately supplied in nutrients.  
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Figure 21: NDUFS3-/- 143B cells trigger glutamine reductive carboxylation  
(A) Determination of the a-KG/citrate ratio following carcinoscope analysis of metabolite levels in 
143B cells cultured in high glucose condition. (B) Mass isotopomer analysis of D [U-13C] glucose 
and (C) L [U-13C] glutamine distribution. Data are means ± SEM of three experiments. ** P<0.01. 
 
 
CI-deficient cancer cells display decreased tumorigenic potential 
 
The metabolic prerequisites for malignancy are complex and ought to be clearly understood. While 
the lack of CI does not affect proliferation in vitro, it can nevertheless be expected that the alteration 
would negatively affects the intricate machinery that drive cancer formation and progression. Several 
methods have been developed to evaluate the tumorigenic potential of cancer cells in vitro, being 
valuable informative primary steps from which further in vivo experiment can be performed. All 
analysis confirmed the hypothesis stated above. The in vitro anchorage independent growth assay in 
soft agar has evidenced the lower ability of CI-deficient clones to grow in an anchorage independent 
atmosphere, compared to CI-competent cells (Figure 22A). The clonogenic assay has showed their 
reduced capacity to survive and to maintain mitotic activity (Figure 22B) and, lastly, the wound 
healing assay showed the lower capability of NDUFS3-/- cells to repopulate the scratched area, 
illustrating their weakened migration ability (Figure 22C). Interestingly, this set of experiments 
suggested that CI loss may have affected more the tumorigenic potential of HCT116 than 143B cells, 
since the difference in all measurements between the two genotypes is higher in the model of 
epithelial origin. Overall, these data demonstrate that CI loss reduces the tumorigenic potential of 
osteosarcoma and intestinal cancer cells in vitro.  
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Figure 22: NDUFS3-/- cancer cells showed reduced tumorigenic potential in vitro 
(A) Representative images of anchorage independent growth in soft agar of HCT 116 and 143B cells 
clones (left), and colony count after 10 days (right). (B) Representative images of clonogenic assay 
results (left) and count of HCT 116 and 143B colonies on soft agar plate after 14 and 10 days, 
respectively (right). (C) Representative images of wound healing assay results (left) and percentage 
of open wound areas after 24 hours for HCT 116 and 143B clones (right). Data are means ± SEM ≥ 
3 experiments * P<0.05; ** P<0.01 
	
	
 
Contrariwise to in vitro studies, in vivo experiments allow the microenvironmental influence on tumor 
progression to be considered. Indeed, vascularization density, oxygen and nutrient availability, 
surrounding cells, molecules and extracellular matrix are inherent to tumor biology. The latter 
characteristics, together with the unstable and always evolving genetics of cancer cells, considerably 
participate to intra-tumoral heterogeneity and render difficult the prediction of tumor evolution. This 
taken into consideration, different strategies have been employed to assess the effects of CI loss on 
tumorigenesis and cancer progression. Both 143B and HCT116 CI-deficient and CI-competent cells 
have been inoculated in nude mice. However, HCT116 NDUFS3-/- failed to engraft (Figure 23), 
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confirming the higher sensibility of the intestinal cancer cells to the suppression of CI activity, as 
evidenced by the previous in vitro experiments (Figure 19A and 20), and restricting in vivo studies to 
the 143B model.  
 
 
Figure 23: HCT116 NDUFS3-/- failed to engraft in vivo 
Xenograft growth after subcutaneous injection of HCT 116 clones in nude mice. NDUFS3-/-  cells 
did not grow. Data are means ± SEM = 8 experiments  
 
In a first experiment, mice were sacrificed when each one of them met the termination criteria, so that 
a proper evaluation of each xenograft growth over time could be performed. Instead, the second 
experiment stopped when the first xenograft reached the maximal volume, hence limiting any time-
related bias for the proper biochemical and molecular characterization of the masses. In both 
experiments, the lack of NDUFS3, confirmed by IHC (Figure 24B), is associated to a significant 
reduction of xenograft growth rate (Figure 24A and 25A) and mice survival (Figure 25B). In line 
with this, less NDUFS3-/- cells presented with positive Ki67 staining, marker of proliferation, 
compared to the WT (Figure 24C).  
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Figure 24: NDUFS3-/- 143B xenografts displayed reduced tumorigenic potential in vivo 
(A) Xenografts growth after subcutaneous injection of 143B clones in nude mice (left), representative 
pictures of the masses after 38 days (right). Data are means ± SEM = 15 animals (B) Representative 
IHC staining of NDUFS3 at 40X magnification. (C) Percentage of KI67 positive cells on tumor slices 
after IHC staining. Data are means ± SEM = 15 samples. 
* P<0.05; ** P<0.01 
 
 
 
Figure 25: NDUFS3-/- 143B xenografts do not recover tumorigenic potential over time 
(A) Xenografts growth after subcutaneous injection of 143B clones in nude mice (B) Proportion of 
animals that reached the termination criteria over time.  Data are means ± SEM ≥ 8 animals; ** 
P<0.01 
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Finally, first in a preliminary experiment (Figure 26 upper panel), and then confirmed by a full 
experiment (Figure 26 lower panel), after that both 143B NDUFS3-/-  and NDUFS3+/+ cells were 
inoculated together in mice, xenografts growths correlated with the abundance of NDUFS3+/+ cells. 
In fact, when more NDUFS3-positive cells were present in the masses (Figure 26B and D), higher 
were the xenograft growth rates (Figure 26A and C). This last data confirmed the tumor advantage 
of having functional CI for growth and progression.   
 
 
Figure 26: Xenograft growth rates correlate with the presence of NDUFS3+/+ cancer cells 
(A) Xenografts growth after subcutaneous injection of a same mix of both 143B CI-deficient and CI-
competent clones at equal proportion in two nude mice (B) IHC staining against NDUFS3 for each 
resulting xenograft, at 40X magnification. (C) Xenografts growth after subcutaneous injection of two 
different cell pools containing both 143B CI-deficient and CI-competent clones at equal proportion 
(P1 and P2), in 3 nude mice for each pool. (D) SDS page followed by western blot analysis on each 
tumor samples (left) and quantification of bands intensity (right). The antibody specifically 
recognizes human NDUFS3. 
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CI-deficient cancer cells are unable to trigger the HIF1- mediated response to hypoxia. 
 
Our group has previously shown the correlation between the absence of CI and the lack of stabilized 
HIF1a. In line with this, western blot analysis indicated that all NDUFS3-/- xenografts lacked HIF1a 
whereas all NDUFS3+/+ xenografts stabilized the transcription factor (Figure 27A), suggesting that 
NDUFS3-/- did not activate any hypoxic response. Accordingly, real-time PCR on the same samples 
showed that the expression of the HIF1 responsive genes VEGF, GLUT1 and LDHA, is significantly 
lower in NDUFS3-/-  than in NDUFS3+/+ xenografts (Figure 27B).  
HIF1 gene expression is not altered in NDUFS3-/-  xenograft, demonstrating that the mechanisms 
responsible for the absence of HIF1a in these masses occur at least at the post transcriptional level 
(Figure 27B).  
 
 
 
Figure 27: NDUFS3-/-  xenografts do no activate the HIF1 pathway 
(A) SDS page followed by western blot analysis on 6 representative tumor samples removed 38 days 
after cell injection, for each genotype. (B)Real-Time PCR after total RNA extraction from xenografts 
tissues. Data are means ± SEM = 3 samples. ** P<0.01; VEGF: vascular endothelial growth factor; 
GLUT1: Glucose transporter 1; LDHA: lactate dehydrogenase. 
 
 
HIF1a stabilization is regulated by both oxygen, a-KG levels and reactive oxygen species (ROS).  
In order to investigate the role of oxygen content, mice were injected subcutaneously with a solution 
of pimonidazole that forms adducts in hypoxia, recognizable by an antibody (Figure 28A). Strikingly, 
no hypoxic adduct was detectable by immunohistochemistry in the NDUFS3-/- xenografts removed 
38 days after mice inoculation, indicating that contrariwise to NDUFS3+/+ masses, they did not face 
hypoxia (Figure 28A). Further, HIF1a staining on the same paraffin sections revealed that CI-
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competent tumors stabilized the transcription factor, with a clear nuclear staining, whereas all CI-
deficient ones did not (Figure 28A).  
 
Figure 28: NDUFS3-/- xenografts do not stabilize HIF1a. 
(A) Illustration of pimonidazole adduct formation in hypoxia (left) and representative IHC staining 
on xenograft samples removed 38 days after cell injection, at 40X magnification (NDUFS3 and 
HIF1a) and at 10X magnification (pimonidazole adducts) (right). NDUFS3-/- xenografts do not show 
any positive staining for each targeted protein. (B) Representative IHC staining for HIF1a (40X) 
and pimonidazole adducts (10X) on xenograft samples removed at maximal volume. The last three 
NDUFS3-/- samples on the right show the absence of HIF1a staining despite the presence of 
pimonidazole adducts. 
 
 
Remarkably, however, when masses were removed at maximum volume, few NDUFS3-/- xenografts 
presented with small hypoxic areas but no stabilization of HIF1a (Figure 28B), suggesting their 
inability to trigger a proper response to hypoxia. Confirming the latter hypothesis, western blot 
analysis showed that both 143B and HCT116 NDUFS3-/- clones delayed HIF1 stabilization when 
cultured in vitro in hypoxia, and ultimately failed to reach the same levels than NDUFS3+/+ with time 
(Figure 29A). Furthermore, upon 24 hours in hypoxia, CI-deficient cell models displayed a 
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significantly lower expression of HIF1-responsive genes compared to CI-competent cells (Figure 
29B).  
 
 
Figure 29: CI-deficient cancer cells display reduced HIF1 activation in vitro in hypoxia 
(A) SDS page followed by western blot analysis on 143B and HCT116 clones cultured in normoxia 
or incubated 30’, 1h or 5h in hypoxia. (B) Real-Time PCR after total RNA extraction from cells 
incubated 24h in hypoxia. Data are means ± SEM = 3 samples; * P<0.05; ** P<0.01 
 
 
Overall, these data are in line with the previous studies conducted by our group that showed the 
pseudonormoxic feature of CI-deficient tumors, arising from their inability to stabilize HIF1a even 
in hypoxic condition, due to NADH accumulation and subsequent rise of a-KG levels that promote 
its proteasomal degradation. In line with this, carcinoscope analysis evidenced a higher NADH/NAD+ 
ratio and increased a-KG levels in 143B NDUFS3-/- clones (Figure 30A and B). Moreover, after cell 
treatment with pimonidazole in hypoxia, western blot analysis indicated that intracellular oxygen 
content of NDUFS3-/- clones was higher than their WT counterparts, as evidenced by the weaker 
bands corresponding to the hypoxic adducts, despite the same extracellular level of oxygen (Figure 
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30C). This is in line with previous studies showing that upon ETC impairment the resulting decrease 
in mitochondrial oxygen consumption participate to raising its cytosolic concentration. 
 
 
Figure 30: NDUFS3-/- 143B clones display a higher NADH/NAD+ ratio and increased 
intracellular levels of a-KG and oxygen  
(A) Determination of the NADH/NAD+ ratio and (B) a-KG by carcinoscope analysis in 143B 
clones cultured in high glucose condition. Data are means ± SEM = 3 samples; * P<0.05. (C) SDS 
page followed by western blot analysis on 143B clones cultured in normoxia or incubated 30’, 1h 
or 5h in hypoxia, in presence or absence of pimonidazole (100µM).   
 
 
 
Finally, the in vitro measurement of H2O2 production in both 143B and HCT116 clones revealed that 
NDUFS3-/- cells had no increase in oxidative stress compared to the NDUFS3+/+ clones (Figure 31). 
In this light, and given the inability of NDUFS3-/- to use the respiratory chain, it is unlikely that ROS 
levels may further increase upon any environmental factors in vivo. 
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Figure 31: NDUFS3-/- clones do not display increased H2O2 production  
Measurements of H2O2 production after cell incubation in a complete high glucose medium 
containing 2,7-dichlorodihydrofluorescein diacetate (H2DCFDA). 
 
Hence, no increase in ROS production and high levels of a-KG and intracellular oxygen may, 
altogether, participate to activate PHDs in CI-deficient cells and xenografts, even in hypoxia (i.e. low 
extracellular oxygen levels). Supporting the latter hypothesis, inhibiting PHDs with DMOG in 
NDUFS3-/- clones restored HIF1a stabilization, and the inhibition of the proteasome by MG132 
induced the accumulation of the hydroxylated form of HIF1a, as observed by western blot analysis 
(Figure 32). Altogether these data suggest that the absence of HIF1a in NDUFS3-/- xenografts may 
originate from intracellular normoxic condition and perturbation of TCA metabolite levels. 
 
Figure 32: Destabilization of HIF1a in NDUFS3-/- clones is cause by its hydroxylation and 
subsequent proteasomal degradation.  
SDS page followed by western blot analysis on 143B and HCT116 clones cultured in hypoxia and 
incubated with DMOG (1mM) or MG132 (10µM) for 5 hours.  
CI-deficient xenografts display a tailored structure that may sustain nutrient supply. 
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Notwithstanding HIF1a destabilization and severe respiration impairment, NDUFS3-/- xenografts 
could sustain a low but constant proliferation rate (Figure 25A), underlying a minimal adaptation to 
meet the growth requirements. Additionally, as mentioned above, CI-deficient cells could sustain 
proliferation only when adequately supplied in nutrients that feed alternative metabolic pathways 
(Figure 17 and 19). In this light, the typical feature of solid tumors that is low vascularization, leading 
to oxygen and nutrient shortage, is expected to be highly deleterious for NDUFS3-/- xenografts growth 
and progression. Surprisingly, immunohistochemical staining directed against CD31, marker of 
endothelial cells, revealed that 143B NDUFS3-/- xenografts may be more vascularized than 
NDUFS3+/+ masses (Figure 33A). Nevertheless, it is important to note that the difficulty to 
discriminate between mature and immature vessels may lower the relevance of this data. Pattern of 
vascularization were nevertheless clearly different between the two genotypes. NDUFS3-/- masses 
presented with clustered vessels that formed extended “highway” septa, while the rest of the tumor 
showed very little and potentially immature vessels (Figure 33B). Contrariwise, NDUFS3+/+ 
xenografts showed rare, scattered but likely mature vessels that were surrounded by cancer cells that 
agglomerated in bulks, delimited by a hypoxic area that separated viable cells from a necrotic area 
(Figure 33C). Further, immunohistochemical analysis of collagen fibres by Masson’s trichrome 
staining, revealed that 143B CI-deficient masses, and not CI-competent ones, displayed stromal 
invasion containing host vessels (Figure 33B and 34). Altogether, these data indicate that CI-deficient 
may have developed a tailored architecture to better respond to the metabolic needs that were required 
for their growth.   
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Figure 33: NDUFS3+/+ and NDUFS3-/- masses display a different pattern of vascularization. 
(A) Quantification of vessels following CD31 staining of all NDUFS3+/+ and NDUFS3-/- xenografts 
removed 38 days after cell injection. Data are means ± SEM = 15 xenografts; * P<0.05. (B) 
Representative IHC staining for CD31 and Masson’s Trichrome staining on NDUFS3-/-  xenograft 
samples removed 38 days after cell injection. Upon Masson’s Trichrome staining, collagen I stained 
in blue, cytoplasm in pink, and nuclei are in dark brown (C) Representative IHC staining for 
pimonidazole adducts, HIF1a and CD31 on NDUFS3+/+ removed 38 days after cell injection. 
 
 
 
 
Figure 34: NDUFS3-/- xenografts present with stromal septa containing vessels. 
Representative Masson’s trichrome staining on xenograft samples removed 38 days after cell 
injection. Upon Masson’s Trichrome staining, collagen I stained in blue, cytoplasm in pink, and 
nuclei are in dark brown. 
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CI removal during tumor progression induces growth arrest  
 
Lack of CI is associated to perturbation in oxygen, ROS and TCA cycle metabolite levels leading to 
HIF1a destabilization, impaired response to hypoxia, and to the trigger of alternative cell metabolic 
pathways and novel tumor architecture, which have most likely progressively settled during tumor 
progression. Despite the lack of a clear understanding of the mechanisms underlying cell metabolic 
and structural adaptation to both biochemical defects and environmental constraints in CI-defective 
xenografts, it can be expected that loss of CI during tumor progression may severely affect tumor 
biology, as cells may already display a specific architecture and metabolic landscape that are adapted 
to their bioenergetic capacity. Hence, and with the aim of reproducing better the patient situation and 
CI loss in oncocytomas, CI was targeted during xenografts progression. 
The NDUFS3 gene, whose expression could be repressed by Dox, was reintroduced in 143B 
NDUFS3-/- clones (NDUFS3-/- ind) (Figure 35). Re-inserting NDUFS3 in CI-deficient cells restored 
CI activity, which was instead suppressed upon treatment with 100ng.ml-1 of Dox (Figure 36). 
Importantly, treatment of NDUFS3+/+ cells with Dox did not affect CI activity, confirming that the 
drug had no side-effect on CI assembly and activity (Figure 36).  
 
 
Figure 35: Doxycycline suppresses NDUFS3 expression in NDUFS3-/- ind cells 
Simplified illustration of the vector containing NDUFS3 whose expression is mediated by a minimal 
CMV promoter that is under the control of a transactivator, inactivated in presence of Dox. The 
system is activated by Dox withdrawal (Left). SDS page followed by western blot analysis on 143B 
NDUFS3-/- ind clones incubated with or without Dox (100ng/mL) during 24hours (Right). 
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Figure 36: The reintroduction of dox-controlled NDUFS3 in NDUF3-/- 143B clones restores CI 
activity 
Clear-Native PAGE followed by CI-in gel activity on NDUFS3-/- mock (containing an empty vector), 
NDUFS3-/- ind and NDUFS3+/+ clones incubated without or without Dox during 9 days. Black bands 
appear only upon NADH oxidation by CI. Ctrl+ is a mitochondrial extract from bovin heart. 
 
 
In vivo experiments without the utilization of Dox showed that the reintroduction of NDUFS3 
restored the tumorigenic potential of 143B cells (Figure 37).  
 
 
 
Figure 37: Re-introducing NDUFS3 restored the tumorigenic potential in vivo 
Xenograft growth after subcutaneous injection of NDUFS3-/- ind and NDUFS3-/- mock clones in nude 
mice. Data are means ± SEM ≥ 5 animals; * P<0.05; ** P<0.01. 
 
 
Contrariwise, when Dox was added to the drinking water of mice, NDUFS3-/- ind xenografts 
progressively stopped growing and mice survival was significantly increased (Figure 38A and B), 
while the treatment did not affect the survival of mice bearing NDUFS3+/+ masses (Figure 38C). 
Immunohistochemical staining against NDUFS3 confirmed that only NDUFS3-/- ind showed loss of 
the CI subunit upon treatment with Dox (Figure 38D). 
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Figure 38: NDUFS3 removal induced growth arrest and increased mice survival 
(A) NDUFS3-/- ind xenografts growth and (B) mice survival after the addition of sucrose (3%) with or 
without Dox (1mg.ml-1) into the drinking water of the animals. (C) Survival of mice bearing 
NDUFS3+/+ xenografts after the addition of sucrose (3%) with or without Dox (1mg.ml-1) into the 
drinking water of the animals. (D) Representative IHC staining of NDUFS3 at 10 and 40X 
magnification of the different xenograft samples.  
 
Altogether, these last data confirm the essential role of the multisubunit complex in cancer 
progression. While re-activating the enzyme in CI-deficient cancer cells rescued xenografts growth 
rate, suppressing its activity during tumor progression stopped tumor growth. In addition, the 
functional link between the respiratory complex and the transcription factor HIF1a is hereby 
demonstrated. In fact, western blot analysis on xenograft samples showed that re-inserting NDUFS3 
in NDUFS3-/- clones rescued HIF1a stabilization, whereas its removal had the reverse effect (Figure 
39). Finally, electron microscopy on xenograft samples revealed a strike difference in their 
ultrastructure. Tumor tissues that have lost NDUFS3 may have accumulated mitochondria with 
disrupted cristae and matrix rarefaction (Figure 40). The difficulty to obtain good quality samples for 
the ultrastructure analysis, however, did not permit to evidence any significance in the results.  
Overall, these data indicate that targeting NDUFS3 and thereby CI during tumor progression may 
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drive cancer cells to develop a more benign oncocytic phenotype, recapitulating HIF1a loss and 
impaired metabolic flexibility through perturbation in NADH/NAD+ ratio, a-KG levels, oxygen 
consumption and ROS production.  
 
Figure 39: HIF1a stabilization strictly depends on CI activity in vivo 
SDS page followed by western blot analysis on 3 representative xenograft samples for each group.  
 
 
 
 
 
Figure 40: Loss of NDUF3 induces the accumulation of mitochondria with strong structural 
impairment 
(A) Representative images of the ultrastructure of NDUFS3-/- ind xenograft samples treated or not 
with Dox. (B) Proportion of mitochondria that display moderate, strong or no mitochondrial defect. 
The latter was defined according to cristae morphology and matrix density. Data are means ± SEM 
= 2 samples. 
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DISCUSSION 
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Over the last two decades, the misconception that mitochondria are just bystanders in the processes 
of tumorigenesis has been progressively ruled out (DeBerardinis and Chandel, 2016). The 
unconventional case of oncocytomas offered an additional striking proof that is worthy of interest: 
high load of CI-disruptive mtDNA mutations are associated with a more benign tumor phenotype. 
Our group has previously showed that shifting mutation load from heteroplasmy towards 
homoplasmy resulted in a strong reduction of CI activity and a lower tumorigenic potential. Further, 
CI-deficient cancer cells lacked HIF1a and displayed impaired metabolic flexibility in hypoxia, while 
accumulating damaged mitochondria (Calabrese et al., 2013; Gasparre et al., 2011b). 
In the present study, we dissected the biochemical and metabolic changes triggered upon CI loss in 
the osteosarcoma and intestinal cancer cell lines 143B and HCT116, respectively, with a focus on 
their capacity to recapitulate a benign phenotype such as the oncocytic features cited above.  
Genome editing allowed us to target NDUFS3 successfully and to abolish CI and OXPHOS activity 
in 143B and HCT116 cells. Despite the severe respiratory deficit induced and a drop in aspartate 
levels, CI loss did not severely affect in vitro cell proliferation, nor it decreased ATP levels. Yet, this 
result could be obtained only when cells were cultured in nutrient rich condition, suggesting their 
ability to compensate CI loss by adjusting nutrient utilization. Accordingly, we observed a higher 
glucose consumption and the trigger of glutamine-dependent reductive carboxylation, which may 
have successfully permitted NDUFS3-/- clones to meet the anabolic and energetic requirements for 
proliferation. Conversely, in vitro and in vivo experiments showed that the tumorigenic potential of 
CI-defective cells was significantly reduced, indicating their inability to meet the metabolic 
requirements that support cell tumorigenic properties. Confirming our previous findings, the lack of 
CI was associated to an increase in the NADH/NAD+ ratio and to higher a-KG levels. Further, we 
showed that NDUFS3-/- clones also presented with a higher concentration of intracellular oxygen 
compared to NDUFS3+/+ clones, even when cultured in condition of extracellular hypoxia. Hence, the 
accumulation of both a-KG and oxygen may have contributed to the significant reduction of 
stabilized HIF1a observed in cells and xenograft samples, which may have significantly participated 
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to limit cell tumorigenic potential. In line with this, we demonstrated that HIF1a redirection toward 
proteasomal degradation is greatly increased in CI-deficient cells. Furthermore, beside oxygen and 
a-KG accumulation, the inability of NDUFS3-/- cancer cells to generate ROS may have been one 
additional factor favouring PHD activation (Figure 41). Noticeably, the lack of CI and OXPHOS 
activity in NDUFS3-/- clones may have also prevented the hypoxia-mediated production of ROS. As 
expected, CI-deficient cells and tumors displayed a lower expression of HIF1-responsive genes 
compared to their WT counterparts, which indicates their inability to trigger the hypoxic response, 
even under low oxygen tension. 
Altogether, these data revealed that although CI-deficient cells can adapt their metabolism to sustain 
proliferation, CI is however required to sustain cell tumorigenic properties.   
Importantly, while several metabolic pathways are dispensable in mono-layer cell culture, increase 
evidence demonstrates that many cancer cell abilities such as cells capacity to grow anchorage-
independently, to migrate and to survive their environment, may drastically modify their metabolic 
dependency (Davidson et al., 2016; Gui et al., 2016; Jiang et al., 2017; LeBleu et al., 2014). In this 
light, we do not exclude the involvement of limiting aspartate levels in the antitumorigenic effects 
observed in CI-defective clones. Indeed, increased nucleotide and amino acid synthesis, including 
aspartate, requires higher levels of NAD+. Interestingly, upon CI inhibition, the latter may be provided 
through increased LDHA activity, which converts pyruvate into lactate, thereby compensating for the 
decrease in CI-mediated NADH oxidation (Gui et al., 2016; Vander Heiden and DeBerardinis, 2017). 
Hence, both the specific cell metabolic requirements and the environment may determine cancer cell 
dependence on NAD+-driven metabolic routes, which may in turn determine cell sensibility to CI 
inhibition (Gui et al., 2016). We showed that the expression of the LDHA gene, target of HIF1, was 
significantly lower in CI-defective xenografts. The latter phenomenon may therefore represent an 
additional bioenergetic restriction that have contributed to the low xenograft growth rate observed in 
vivo (Figure 41). 
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Beside regulating the HIF1 pathway, it is important to note that a-KG is also a signal of amino acid 
availability (Durán et al., 2013). Dysregulated levels of the metabolite may have therefore further 
perturbed cell adaptation to nutrient limitation in CI-defective xenografts. In addition, a-KG and its 
derivatives may also affect the all family of Fe(II)/a-KG dependent dioxygenases, with important 
consequences at both metabolic and epigenetic levels. In this frame, we have recently discussed the 
role of a-KG in cancer progression, which can be dual, as it may promote both oncogenic and tumor 
suppressive functions (Vatrinet et al., 2017). Hence, the a-KG signal may contribute to the overall 
reprograming of cancer cell function to ensure their survival, or it may instead perturb cell response 
to internal and external pressures when dysregulated. Discriminating the role of the metabolite in 
modifying the tumorigenicity of CI-deficient cancer cells still ought to be understood more clearly. 
Notwithstanding the decrease in xenografts growth rate, long term in vivo experiments have shown 
that the lack of CI did not prevent tumors formation and progression, suggesting that they have 
successfully met the metabolic requirements to sustain biomass production. The latter phenomenon 
could be explained by their ability to revise nutrient utilization, as observed in vitro, albeit it would 
have required abundant resources that are known to be limited in vivo. Furthermore, NDUFS3-/- cells 
displayed a lower expression of VEGF, master regulator of vascularization that is normally expressed 
upon HIF1 activation. Strikingly, however, CI-deficient xenografts presented with stromal invasion 
containing vessels, which were therefore likely to supply cells with nutrients. This finding shed light 
on a two-way relationship between the tumor environment and cancer cell metabolism, as each of the 
two may affect the other. CI-deficient cells may benefit from high levels of glucose and glutamine, 
the two major nutrients utilized by cancer cells, which are found in abundance in the blood (Hosios 
et al., 2016). Additionally, several studies have revealed the capacity of cancer cells to scavenge many 
extracellular molecules as proteins, acetate, fatty acids and lipids (Commisso et al., 2013; 
Michalopoulou et al., 2016; Palm et al., 2015). The latter mechanism is further favoured by the often 
poorly constructed and leaky vessels found in tumors, which may allow large complex and 
macromolecule as albumin and lipoprotein to feed the cells (Michalopoulou et al., 2016). Therefore, 
83 
it is plausible that CI-deficient xenografts may have rearranged their architecture to circumvent their 
poor metabolic flexibility. The mechanism through which CI-deficient xenografts have attracted host 
vessels remains to be investigated.  
Finally, NDUFS3 was removed while xenograft already reached advanced development stage. In this 
context, we showed that xenografts arrested their growth and that CI loss induced HIF1a 
destabilization, hence confirming the functional link between the transcription factor and the 
enzymatic complex. In addition, removing NDUFS3 from xenografts have successfully recovered 
one key oncocytic feature that is the accumulation of defective mitochondria. 
Overall, these findings indicate that targeting CI during tumor progression may redirect them towards 
a more benign oncocytic phenotype. While CI-deficient tumors developed tailored solution to sustain 
their growth, it is likely that the cell metabolic restriction induced by CI sudden loss induces cells 
incapacity to face the existent environmental condition, notably due to their inability to stabilize 
HIF1a. In the future, re-activating this transcription factor in CI-deficient xenografts and suppressing 
its stabilization in CI-competent ones will be useful strategies that will help to confirm the pivotal 
role of HIF1a loss in preventing tumor growth, together with discriminating the relative significance 
of CI disruption in carcinogenesis and cancer progression. 
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Figure 41: CI loss induces HIF1a destabilization and impair cell metabolic flexibility 
ROS, O2, and a-KG regulate HIF1a stabilization through PHD activity. The lack of ROS and the 
increase in the levels of O2 and a-KG may induce HIF1a destabilization in CI-deficient cancer cells. 
HIF1 is a known enhancer of glycolysis, glutamine-dependant anaplerosis, and tumor 
vascularization, thus impaired upon CI loss. Homeostasis of NADH/NAD+ ratio is required to drive 
essential biosynthetic pathways. Lack of CI may significantly reduce amino acids (AA) and NT 
(nucleotide) synthesis, which are dependent on mitochondrial metabolites exchange through the MAS 
shuttle, which is sensitive to high NADH/NAD+ ratio. The latter may be further maintained at high 
levels due to limited HIF1-mediated pyruvate conversion in lactate that would partly restore NADH 
oxidation. Lack of OXPHOS activity may be responsible for reduced ATP levels and energetic crisis 
in condition of nutrient limitation.  
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a  b  s  t  r  a  c  t
In  the  last  10  years,  studies  of energetic  metabolism  in different  tumors  clearly  indicate  that  the  definition
of  Warburg  effect,  i.e. the  glycolytic  shift  cells  undergo  upon  transformation,  ought  to  be  revisited  consid-
ering  the metabolic  plasticity  of  cancer  cells.  In  fact,  recent  findings  show  that  the  shift  from  glycolysis  to
re-established  oxidative  metabolism  is  required  for certain  steps  of  tumor  progression,  suggesting  that
mitochondrial  function  and,  in particular,  respiratory  complex  I are crucial  for  metabolic  and  hypoxic
adaptation.  Based  on these  evidences,  complex  I  can  be considered  a lethality  target  for  potential  anti-
cancer  strategies.  In conclusion,  in  this  mini  review  we summarize  and  discuss  why  it  is not  paradoxical  to
develop  pharmacological  and  genome  editing  approaches  to  target  complex  I as  novel  adjuvant  therapies
for cancer  treatment.
This  article  is  part  of a Directed  Issue  entitled:  Energy  Metabolism  Disorders  and  Therapies.
© 2015  Elsevier  Ltd. All  rights  reserved.
1. Introduction
Metabolic reprogramming is currently recognized as one of the
hallmarks of cancer (Hanahan and Weinberg, 2011). In particular,
cancer cells are characterized by increased glycolytic metabolism
regardless of the availability of O2, as observed for the first time by
Otto Warburg, who hypothesized that such metabolic preference
was a consequence of dysfunctional mitochondria. Indeed, loss-of-
function mutations have been identified in human cancers (Kirches,
2009) and it has been shown that carcinogenesis is associated
Abbreviations: OXPHOS, oxidative phosphorylation; CI, complex I; ROS, reac-
tive  oxygen species; TCA, tricarboxylic acid; PARP1, poly (ADP ribose) polymerase
1;  AMPK, AMP  activated kinase; mTORC1, mammalian target of rapamycin com-
plex 1; HIF1!, hypoxia inducible factor 1!; PDC, pyruvate dehydrogenase complex;
IDH, isocitrate dehydrogenase; !KG-DH, !-ketoglutarate dehydrogenase; !KG, !-
ketoglutarate; SA, succinate; PHD, prolyl hydroxylase; ZNFs, zinc finger nucleases;
TALENs, transcription activator-like effector nucleases; CRISPR, clustered regularly
interspaced short palindromic repeats; Cas, CRISP-associated.
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Key facts:
• Respiratory complex I impairment impinges on cancer pro-
gression.
• Complex I function is required for the induction of a Warburg
profile.
• Targeting Complex I is a potential adjuvant anti-cancer strat-
egy.
with decreased levels of mitochondrial proteins and upregulation
of glycolytic enzymes (Cuezva et al., 2002). However, Warburg’s
hypothesis has been somewhat revisited with time, since it has
been found that certain tumors maintain oxidative metabolism
during tumor progression (Bellance et al., 2009). In fact, oxidative
phosphorylation (OXPHOS) and in particular respiratory complex
I (CI) are crucial not only for energy generation, maintenance of
redox homeostasis, and reactive oxygen species (ROS) production,
but they are also indirectly involved in the regulation of biosyn-
thetic pathways (DeBerardinis et al., 2008).
CI is a multi-subunit enzyme whose main function is to oxi-
dize the NADH produced through glycolysis and tricarboxilic acid
(TCA) cycle to NAD+, and to transfer electrons to ubiquinone.
http://dx.doi.org/10.1016/j.biocel.2015.01.017
1357-2725/© 2015 Elsevier Ltd. All rights reserved.
42 R. Vatrinet et al. / The International Journal of Biochemistry & Cell Biology 63 (2015) 41–45
Fig. 1. Representation of the biochemical and molecular impact of CI dysfunction. Non functional CI leads to increased AMP/ATP ratio, decreased NAD+/NADH balance, and
potentially ROS levels alteration that directly impinge on several pathways involved in metabolic and hypoxic adaptation essential for tumor progression. NADH accumulation
and  ATP depletion slow down tricarboxylic acid (TCA) cycle, inhibiting the !-ketoglutarate dehydrogenase (!KG-DH), which in turn may result in an imbalance of !KG/SA
toward !KG that promotes prolyl-hydroxylase (PHD) activity. Constitutive activation of PHD leads to HIF1! degradation regardless of O2 tension. NADH accumulation
and  ATP depletion inhibit also pyruvate dehydrogenase complex (PDC) and isocitrate dehydrogenase 3 (IDH3), preventing the conversion of pyruvate to acetyl-CoA and
promoting alternative metabolic strategies, such as glutaminolysis and reductive carboxylation, to feed biosynthetic pathways. Moreover, mutated forms of IDH1/2 produce
the  oncometabolite 2-hydroxyglutarate, known to induce epigenetic modifications. In pathological context such as cancer and/or OXPHOS impairment, the cytosolic LDH
can  convert pyruvate to lactate leading to extracellular environment acidification. NAD+/NADH imbalance, energy depletion, and altered ROS levels due to CI impairment
also  regulate specific signaling cascades (i.e., Sirtuins, AMPK/mTORC1, PGC-1!,  PI3K) involved in metabolic reprogramming, hypoxic adaptation, DNA integrity, cell growth,
and  proliferation.
This process is coupled to the release of 4H+ from the mito-
chondrial matrix to the intermembrane space, providing the
electrochemical gradient necessary for ATP production. As a
by-product of these reactions, CI may  generate ROS, especially
under certain pathologic conditions. Therefore, it is not surpris-
ing that CI has been recently recognized as a key player in
cancer development and progression (Iommarini et al., 2013).
Interestingly, ours and other groups showed that severe CI dys-
functions can be disadvantageous to tumor growth (Gasparre
et al., 2011; Park et al., 2009) and that a minimal CI function is
required for the induction of a Warburg phenotype, disclosing this
enzyme as a potential target for cancer therapy (Calabrese et al.,
2013).
2. Respiratory complex I as a modulator of tumor
progression
Several mechanisms have been proposed through which CI dys-
function may  impinge on tumor progression, all of which may
provide potential therapeutic targets. In particular, impairment
of CI can be reflected on the cellular redox balance and energy
charge, represented by ROS, NAD+/NADH, and AMP/ATP, respec-
tively (Fig. 1). Defective CI may  increase ROS levels, which on one
hand are known to activate pro-tumorigenic signaling (Ray et al.,
2012), and on the other, may  be toxic when chronically overpro-
duced (Shen et al., 1998). It is noteworthy that oxidative stress can
occur when CI is only partially defective (Ishikawa et al., 2008;
Sharma et al., 2011), whereas no significant increase in ROS pro-
duction has been observed in cancer models bearing severe CI
dysfunction, most likely due to the lack of the CI sites where ROS
are generated (Iommarini et al., 2014; Gasparre et al., 2011). The
maintenance of the redox and energetic homeostasis is essential
to determine cell fate, and when these balances are altered cells
attempt to respond by re-routing metabolic reactions and trigger-
ing different signaling pathways. In particular, the NAD+/NADH
balance regulates the Sirtuins-dependent signaling pathway and
poly (ADP ribose) polymerase 1 (PARP1) mediated control of
DNA integrity and cell proliferation. Those pathways have been
widely linked to neoplasia, highlighting the relevance of the NAD
metabolome in cancer (Chiarugi et al., 2012). Interestingly, we have
previously demonstrated that cancer cells carrying severe CI defect
show decreased NAD+/NADH ratio due to NADH accumulation
associated with reduced tumorigenic potential (Calabrese et al.,
2013), indicating that CI dysfunction may  generate an inhibitory
signal for Sirtuins and trigger adaptive responses (Fig. 1). All the
seven human Sirtuins (SIRT1-7) have been involved in cancer in
some way, but whether they play a tumor suppressor or oncogenic
role seems to depend on the cellular and molecular context. For
example, SIRT1 overexpression reduces the spontaneous forma-
tion of carcinomas and sarcomas (Herranz et al., 2010), but it has
also been found highly expressed in different human cancers (Yuan
et al., 2013a,b), where it promotes carcinogenesis and resistance to
chemotherapy (Herranz et al., 2013; Liang et al., 2008; Chen et al.,
2012). Similarly, mitochondrial SIRT3 and SIRT5 have been found
overexpressed in some types of cancer (Alhazzazi et al., 2011; Yan
et al., 2014; Lu et al., 2014) and their knock down represses cell pro-
liferation and tumor formation. Nonetheless, they have been also
found down-regulated in other tumors (Yang et al., 2014; Lai et al.,
2013) and they may act as tumor suppressors by regulating ROS
production and hypoxic response (Finley et al., 2011). Conversely,
SIRT4 seems to act exclusively as a tumor suppressor by restricting
glutamine utilization and repressing Myc-induced B cells lym-
phomagenesis (Jeong et al., 2013; Jeong et al., 2014). Owing to a
crucial role in energy production, CI dysfunctions have been also
associated with altered AMP/ATP ratio and increasing evidences
demonstrate that cellular energetic crisis may impact on tumor
progression despite the enhanced glycolysis (Guo et al., 2011; Jones
et al., 2005). Nutrient deprivation commonly experienced by cancer
cells during tumor progression triggers the activation of the energy
sensor AMP  activated kinase (AMPK), which inhibits biosynthetic
pathways and supports catabolic events in order to restore intra-
cellular energetic balance (Hardie et al., 2012). Moreover, AMPK
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down-regulates the mTORC1 signaling, preventing cell growth and
proliferation, and suppresses the translation and therefore the
transcriptional activity of Hypoxia Inducible Factor 1! (HIF1!),
the master regulator of hypoxic adaptation (Faubert et al., 2013).
Interestingly, lack of AMPK induced a metabolic shift toward aer-
obic glycolysis in a HIF1!-dependent mechanism, suggesting that
AMPK acts as a tumor suppressor by down-modulating the HIF1!-
mediated Warburg effect (Faubert et al., 2013). We  recently showed
that malignant cells carrying severe CI defects displayed a striking
increase in AMP/ATP ratio and AMPK activation under metabolic
stress conditions (Iommarini et al., 2014), meaning that CI targeting
could affect AMPK activation (Fig. 1). However, such compensatory
strategy to energy depletion did not influence cell proliferation,
which was rather controlled by HIF1! in an AMPK-independent
mechanism, at least in vitro under normoxic conditions (Iommarini
et al., 2014). Hence, the intricate molecular events linking CI to
Sirtuins and AMPK pathways in tumor progression seem to be
context- and environment-dependent, highlighting the plasticity of
metabolic reprogramming in modulating cell adaptation to stress
stimuli.
It is well known that CI controls the rate of glycolysis and
TCA cycle, allosterically regulating their main checkpoints, namely
the pyruvate dehydrogenase complex (PDC), isocitrate dehydro-
genase (IDH) and !-ketoglutarate dehydrogenase (!KG-DH). In
order to sustain high glycolytic metabolism and regenerate the
NAD+ pool, cancer cells preferentially convert pyruvate to lactate,
thus uncoupling the mitochondrial metabolism from glycolysis
and causing extracellular environment acidification (DeBerardinis
et al., 2008). In such context, it is not surprising that the TCA
gatekeeper PDC has been found critical for cancer cell prolifera-
tion, since it reduces oncogene-induced senescence (Kaplon et al.,
2013) and promotes the Warburg effect (Fan et al., 2014). Nonethe-
less, CI defective cells showed low levels of PDC subunits E1"
and E3, and decreased activity under metabolic stress conditions
(Musicco et al., 2014). These findings suggest that TCA cycle check-
points may  be regulated in a non-canonical manner under unusual
metabolic states, such as NADH accumulation accompanied with
ATP depletion, found in CI-deficient cells. In fact, to sustain cell
proliferation, cancer cells can bypass PDC inactivation by convert-
ing pyruvate to oxaloacetate via pyruvate carboxylase (Cheng et al.,
2011) or by using reductive carboxylation of glutamine as an alter-
native carbon source for citrate biosynthesis (Mullen et al., 2011).
Interestingly, reductive carboxylation involves IDHs and !KG-DH,
which are the other two enzymatic TCA cycle checkpoints reg-
ulated by CI function, directly (IDH3) or indirectly (IDH1/2) via
NADH accumulation. Despite the fact that IDH1 and IDH2 have
been found mutated in different types of cancer (Yan et al., 2009;
Mardis et al., 2009), they acquire a neomorphic function through
the production of the oncometabolite 2-hydroxyglutarate, indi-
cating that their effects on tumor growth are not exclusively
exerted through a CI-related mechanism. Lastly, NADH accumu-
lation and ATP depletion caused by CI defects may  allosterically
inhibit !KG-DH with subsequent unbalance of !KG/succinate (SA)
ratio, leading to HIF1! destabilization and in turn to progression
toward malignancy. In fact, !KG/SA ratio controls HIF1! degra-
dation by regulating the prolyl-hydroxylases (PHDs) activity and
!KG is also required for reductive carboxylation in mitochon-
drial defective cancer cells (Mullen et al., 2014). Regardless of
the oxygen tension level, cells exposed to permeable derivatives
of !KG displayed increased HIF1! degradation (Tennant et al.,
2009), whereas high SA levels promote HIF1! chronic stabilization
(Pollard et al., 2005). Interestingly, CI-defective cells displayed an
unbalance in !KG/SA ratio and constitutive destabilization of HIF1!
(Gasparre et al., 2011; Calabrese et al., 2013; Iommarini et al., 2014)
(Fig. 1). These cells were unable to induce a glycolytic shift dur-
ing hypoxic adaptation and to generate a Warburg profile in vitro
and in vivo, thus hampering tumor growth (Calabrese et al., 2013).
These data indicate that respiratory CI is essential for the induc-
tion of the Warburg effect and adaptation to hypoxia of cancer
cells.
Overall, considering the above mentioned metabolic plasticity
and the essential role of CI in controlling metabolism, hypoxic adap-
tation and cell proliferation, this enzyme may be envisioned as an
intriguing target for development of new anticancer agents. In par-
ticular, these compounds may  be considered for adjuvant therapies
in combination with other drugs targeting peculiar features of can-
cer cells such as metabolic and proliferative pathways (Cairns et al.,
2011).
3. Targeting complex I as an anticancer strategy
A large panel of pharmacological compounds affecting CI has
been proposed and studied as anticancer drugs (Table 1). Specific
CI inhibitors, such as the plant alkaloid rotenone, piericidin A and
capsaicin have been shown to be selectively cytotoxic for can-
cer cells under metabolic stress conditions (Palorini et al., 2013).
Recently, biguanides have been recognized as a new class of CI
inhibitors, preventing ubiquinone reduction in a non-competitive
manner and stimulating ROS production (Bridges et al., 2014).
In particular, the widely used anti-diabetic drug metformin has
been found to exert anti-neoplastic effects, as documented by
clinical studies which highlighted a potential reduction of risk
of cancer in patients treated with the drug (Evans et al., 2005;
Becker et al., 2014). Accordingly, several studies in vitro and in vivo
provided a body of evidence for metformin-mediated anti-
neoplastic effects (Wheaton et al., 2014; Andrzejewski et al.,
2014). In particular, cancer cells with OXPHOS defects or glu-
cose utilization impairment were found to be more prone to
respond to CI inhibition by biguanides (Birsoy et al., 2014). More-
over, metformin and phenformin have been already shown to
enhance the anti-proliferative effect of BRAF inhibitors in BRAF-
mutated melanoma cell lines (Niehr et al., 2011; Yuan et al.,
2013a,b). Therefore, CI may  be envisioned as a lethality tar-
get for potential adjuvant anticancer strategies, in combination
with anti-proliferative or anti-glycolytic drugs. Such targeting
of both oxidative and glycolytic cells might prevent tumor
relapse due to cancer heterogeneity and its constant metabolic
adaptability.
The molecular mechanisms by which biguanides affect can-
cer cell metabolism and proliferation are still unclear. In fact,
biguanides may  influence other enzymes, such as ATP synthase
[Bridges et al., 2014), and they contribute to the regulation of
insulin-like growth factor signaling (Xie et al., 2014). Since spe-
cific CI inhibitors displayed adverse effects and biguanides have
been shown to have wide-spread response, the druggability of
CI results weakened, highlighting the necessity of a step for-
ward in drug design and in molecular approaches. An alternative
strategy would be to envisage the use of emerging genome
editing technologies, such as Zinc Finger Nucleases (ZFNs), tran-
scription activator-like effector nucleases (TALENs) and clustered
regularly interspaced short palindromic repeats/CRISP-associated
(CRISPR/Cas). These are site-specific nucleases that efficiently
induce DNA modifications, such as insertions and deletions, at
user-defined genetic locations, leading to gene disruption. Indeed,
such molecular approaches have been already tested to target
nuclear and mitochondrially-encoded CI genes (Bacman et al.,
2013; Stroud et al., 2013) and represent promising implements
for functional studies on CI, meeting the capability to dissect the
molecular and biochemical mechanisms underlying the poten-
tial anti-tumorigenic effect of its disruption, in CI-free engineered
models.
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Table 1
Respiratory complex I inhibitors used as anticancer molecules.
Inhibitor (class)# Family of compounds Mechanism of action References
Piericidin A (I/A) Piericidins -Induces cell death in association with glucose starvation
-Synergistic effect with Forskolin
Hwang et al., 2008; Palorini et al., 2013
Rotenone (II/B) Rotenoids -Induces cell death in association with glucose starvation
-Synergistic effect with Forskolin
Palorini et al., 2013; Wheaton et al., 2014
Capsaicin (C) Vanilloids -Induces cell death in association with glucose starvation
-Synergistic effect with Forskolin
-Stimulates ROS production and promotes apoptosis
Pramanik et al., 2011; Palorini et al., 2013
Rolliniastatin-1 (I/A) Annonaceus acetogenins -Induces the mitochondrial apoptotic pathway de Pedro et al., 2013
Metformin Biguanides -Reduces HIF1! stabilization under hypoxia
-Activates AMPK pathway
-Modulates IGF pathway
Wheaton et al., 2014; Andrzejewski et al.,
2014; Birsoy et al., 2014
Phenformin Biguanides -Reduces HIF1! stabilization under hypoxia
-Activates AMPK pathway
-Modulates IGF pathway
Wheaton et al., 2014; Birsoy et al., 2014
BAY 87-2243 Aminoalkyl pyrimidine -Prevents HIF1! stabilization under hypoxia Ellinghaus et al., 2013
# Classification by mechanism of inhibition is available only for canonical respiratory complex I inhibitors.
4. Conclusions and perspectives
Based on the evidences here discussed that respiratory complex
I is a modulator of cancer metabolism, it can be stated that targeting
CI to prevent the Warburg effect is not paradoxical. In fact, recent
advances demonstrated that the Warburg hypothesis must be rein-
terpreted considering that cancer cells need a functional OXPHOS
to progress toward malignancy. Owing to the crucial role of CI in the
regulation of hypoxic and metabolic adaptation and to its ability to
determine cell fate under selective tumor microenvironment, this
enzyme can be envisioned as a lethality target for novel potential
anticancer strategies. New advances in drug design and genome
editing techniques will represent valuable tools to improve the
development of adjuvant therapies for cancer treatment.
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The α-ketoglutarate dehydrogenase
complex in cancer metabolic plasticity
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Abstract
Deregulated metabolism is a well-established hallmark of cancer. At the hub of various metabolic pathways deeply
integrated within mitochondrial functions, the α-ketoglutarate dehydrogenase complex represents a major
modulator of electron transport chain activity and tricarboxylic acid cycle (TCA) flux, and is a pivotal enzyme in
the metabolic reprogramming following a cancer cell’s change in bioenergetic requirements. By contributing to
the control of α-ketoglutarate levels, dynamics, and oxidation state, the α-ketoglutarate dehydrogenase is also
essential in modulating the epigenetic landscape of cancer cells. In this review, we will discuss the manifold
roles that this TCA enzyme and its substrate play in cancer.
Keywords: α-Ketoglutarate dehydrogenase complex, α-Ketoglutarate, Mitochondrial function, Metabolic stresses,
Cancer plasticity, Cell signaling, Oncometabolite, Epigenetics
Background
Cancer cells must acquire several biological properties
in order to survive, proliferate, and disseminate. These
functional features, or “hallmarks of cancer”, comprise
sustaining proliferative signaling, evading growth sup-
pressors, escaping cell death, and activating invasion/
metastasis, all of which conspire to lead to pathologically
high levels of cell survival and growth, and ultimately
tumorigenesis [1]. In the last 10 years, an increasing
number of studies suggests that cancer cells reprogram
their metabolism in order to most effectively support
growth and proliferation. Thus, metabolic rewiring has
become an additional hallmark of cancer [1]. Increased
aerobic glycolysis, as initially described by Otto Warburg
[2], is observed in the majority of neoplasms in vivo,
where it is believed to confer advantages to cancer cells
for the production of energy, biomass, and reducing
equivalents [3]. Although Warburg hypothesized that
such a biochemical phenotype arises from the accumula-
tion of mitochondrial defects, it is now known that,
upon nutrient deprivation, oxidative metabolism can
be promptly re-established, and a significant level of
OXPHOS is maintained both in vitro and in vivo [4–9].
A common feature of solid tumors is that cells rapidly
accumulate in bulks, with limited blood supply, and will
hence cope with fluctuations in oxygen and nutrients,
which will inevitably force them to modulate mitochon-
drial function consequently. Interestingly, it has been
shown that neither hypoxia nor OXPHOS defects imply
a complete shutoff of mitochondrial metabolism, and in
either case the tricarboxylic acid (TCA) cycle may ad-
just metabolic fluxes to promote a glutamine-
dependent biosynthetic pathway that sustains tumor
progression [10]. Hence, the TCA cycle represents a
metabolic hub that drives substrate utilization upon
changes in resources availability. With respect to this,
the discovery of mutations in genes encoding key
enzymes of the TCA cycle has brought into light the
importance of intracellular TCA cycle metabolite levels
in modifying both the metabolic and the epigenetic
landscape of cancer cells. Modification of TCA meta-
bolic fluxes and metabolites levels in response to envir-
onmental pressures might therefore account for tumor
adaptation and plasticity in the changing environment.
In this frame, the α-ketoglutarate dehydrogenase complex
(α-KGDC) stands out as being deeply interconnected
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with the respiratory chain, tightly regulated upon tumor
microenvironmental changes, a modulator of the level
of the signaling metabolite α-ketoglutarate (α-KG), a
regulator of cellular redox state, and at the crossroads
of numerous metabolic routes. In this review, we will
discuss the manifold roles this enzymatic complex and
its substrate α-KG play in cancer.
Main text
The α-KGDC in cell metabolism
The TCA cycle is fueled by substrates entering at different
gateways to convey the carbon source for both energy
production and biosynthesis. In the canonical view, acetyl
CoA is provided by the oxidation of carbohydrates, mostly
glucose and fatty acids, and is then condensed with oxalo-
acetate to form citrate. The subsequent series of oxidative
reactions leads to the production of the reducing equiva-
lents NADH and FADH2 that feed respiratory complex I
(CI) and respiratory complex II (CII), respectively, to
generate the mitochondrial membrane potential (Δψm)
required for ATP production. Glutamine, the most
abundant amino acid in the plasma, has been widely
described as an additional key source of both carbon
and nitrogen, especially for fast proliferating cells [11].
Glutaminolysis results in the production of α-KG, either
following dehydrogenation of glutamate or through a
transamination reaction. In turn, α-KG can fuel both
energetic and anabolic pathways: it may be oxidized by
the α-KGDC inside the mitochondria or it may be re-
duced, thereby pushing the TCA cycle towards citrate
[10, 12–14]. The latter may be extruded to the cytosol,
where it may be converted back into acetyl CoA, and
thereby used for lipid biosynthesis.
Hence, the manifold mitochondrial functions allow cells
to rely on different sources of nutrients for energetic and
anabolic purposes. How cells balance the utilization of
these nutrients depends on key metabolic enzymes, whose
activities are modulated in response to genetics and envir-
onmental pressures. In this light, the α-KGDC lies at the
very hub of metabolic pathways and its activity is finely
regulated by the levels of ATP, ADP, inorganic phosphate
(Pi), and by the NADH/NAD+ ratio, which are tightly
dependent on the respiratory chain activity and on the rate
of the glycolytic flux. The product of the α-KGDC reac-
tion, succinyl CoA (Succ-CoA), has been shown to exert a
direct control on the enzyme activity along with calcium
(Ca2+) and reactive oxygen species (ROS) (Fig. 1). Further,
variations of mitochondrial pH and oxygen levels also
Fig. 1 Regulation mechanisms of α-KGDC. α-KGDC is a complex consisting of multiple copies of three enzymes: α-ketoglutarate dehydrogenase
(E1), dihydrolipoamide succinyltransferase (E2), and dihydrolipoamide dehydrogenase (E3). α-KG reacts with the TPP that binds E1, and is thereby
a decarboxylated-generating hydroxyethyl compound. E1 also catalyzes the transfer of two electrons and the acetyl group of the TPP on lipoic
acid (LA), which is bound to the E2 subunit. The reaction performed by E2 is a transesterification in which the thiol group of the Coenzyme A
(CoA) replaces the thiol group of E2, producing Succ-CoA and the reduced form of the lipoic group, the dihydrolipoic acid (DHLA). The sub-
unit E3 catalyzes the transfer of two atoms of hydrogens from DHLA to its prosthetic group FAD, restoring oxidized LA. The reduced FADH2
of the E3 enzyme transfer H+ to NAD+ to form NADH.
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appear to be involved in the regulation of the enzyme.
Hence, the multifactorial modulation of α-KGDC function
may reflect its key role in orchestrating the responses to
the ever-changing metabolic requirements of a cancer cell.
How the α-KGDC contributes to adapt mitochondrial
metabolism to bioenergetic requirements
Structure and energetic regulation of the α-KGDC
In the TCA cycle, the α-KGDC catalyzes the reaction
between α-KG and CoA, using thiamine pyrophosphate
(TPP) as a cofactor and reducing the pyridine nucleotide
NAD+ to NADH, finally generating succ-CoA and CO2.
The α-KGDC is a multienzyme complex composed of
three subunits (Fig. 1). The E1 subunit, encoded by the
human OGDH gene, is a dehydrogenase that catalyzes
the decarboxylation of α-KG, the first step required to
produce succ-CoA. The second step is the reductive suc-
cinylation of the dihydrolipoyl groups, a reaction carried
out by the E2 subunit, i.e., the dihydrolipoamide succi-
nyltransferase, encoded by the human DLST gene. The
E3 subunit, encoded by the human DLD gene, is the
dihydrolipoamide dehydrogenase, which catalyzes the re-
oxidation of the E2 dihydrolipoyl groups, eventually re-
ducing the final acceptor NAD+ to NADH [15]. The
regulation of the α-KGDC highlights a dynamic interplay
between the enzyme and the OXPHOS to adjust mito-
chondrial metabolism through cell energy status sensing.
Both the E1 and the E3 subunits are inhibited by NADH
[16], which accumulates following a decrease of CI func-
tion [17]. Indeed, the latter complex is the first and the
largest of the respiratory chain and catalyzes NADH oxi-
dation to transfer electrons to flavin mononucleotide,
which are used to reduce coenzyme Q to ubiquinol
(QH2). The latter is subsequently used by complex III to
reduce cytochrome c in the mitochondrial intermem-
brane space (IMS), and complex IV uses cytochrome c
to reduce molecular oxygen, which is the final electron
acceptor [18]. Hence, CI actively participates to the gen-
eration of the electrochemical gradient by feeding the
ETC to generate ATP, which makes NADH an essential
substrate for oxidative metabolism. Interestingly, evi-
dence is given for the existence of a direct interaction
between CI and α-KGDC, which not only would provide
an effective NADH oxidation mechanism via substrate
channeling compared to free diffusion [19–21] but also
implicates a higher sensitivity of α-KGDC to NADH
levels, placing the enzyme on the front line to adapt to
variations in ETC efficiency. In addition, a high ADP/
ATP ratio and a high concentration of Pi independently
enhance the activity of the α-KGDC, with a low ADP/
ATP ratio having opposite effects [22, 23]. The levels of
Pi and ADP are indicators of a low energetic condition,
and both molecules act as positive effectors by increas-
ing the affinity of the enzyme for its substrate.
Conversely, higher ATP levels increase the amount of
substrate necessary to reach the half-maximum rate of
the enzyme, therefore reducing its activity [22, 24]. The
regulation of α-KGDC by both the adenine nucleotide
phosphorylation state and the NADH/NAD+ ratio is
tightly dependent on the Δψm: on the one side, ATP ex-
trusion from the mitochondria to the cytosol is con-
trolled by the ADP/ATP carrier that is regulated by high
Δψm and exchanges ATP with ADP in a 1:1 ratio [25].
On the other side, in cases when the ETC is damaged,
the production of mitochondrial NADH, driven by cyto-
solic reductive power, is decreased [26]. This implies that
the energetic control on the α-KGDC might be exclu-
sively mitochondrial, and that a feedback loop relying on
both substrate and energy availability is triggered be-
tween the OXPHOS and the enzyme, thereby ensuring
an optimal cooperation. In this light, it may be envi-
sioned that a decrease in mitochondrial respiration, or a
significant ATP accumulation, may be associated with a
decrease in α-KGDC activity. Changes in the enzyme
function would in turn balance mitochondrial NADH
levels, thus modulating CI activity and thereby ATP pro-
duction. However, it has been observed in human neuro-
blastoma cells that decreasing α-KGDC activity up to half
its maximum decreases neither Δψm nor mitochondrial
ATP levels [27]. In line with this, the existence of a thresh-
old for the α-KGDC capacity has been demonstrated,
which can be greatly inhibited before affecting the max-
imal mitochondrial oxygen consumption rate [28]. NADH
levels can therefore vary broadly before becoming a limit-
ing factor for cellular respiration, suggesting that any re-
duction of α-KGDC activity might represent a first
attempt to adapt metabolism by modulating TCA flux, be-
fore impinging on ETC function.
Calcium-mediated regulation of the α-KGDC
The relationship between α-KGDC and Ca2+ further em-
phasizes the pivotal role of the enzyme in regulating cell
metabolism. The mitochondria have long been thought
to be a Ca2+ sink, with the main scope of regulating this
cation homeostasis in cells. Cytosolic Ca2+ has been
shown to foster NADH oxidation by the glycerol de-
hydrogenase to ultimately produce and import FADH2
within the mitochondria as a substrate for CII [29]. Fur-
thermore, Ca2+ stimulates NADH production through
the reactions of the TCA enzymes pyruvate dehydrogen-
ase (PDH), isocitrate dehydrogenase (IDH) and α-KGDC
[16, 30]. Among these three enzymes, α-KGDC has been
shown to be the most responsive to Ca2+, as the cation
lowers the enzyme KM for α-KG [22, 25, 29, 31]. Interest-
ingly, the sensibility of α-KGDC to Ca2+ depends on the
concentration of NADH, and on the ATP/ADP ratio, again
highlighting a regulatory role of the ETC on the enzyme ac-
tivity. Indeed, an increase in both cofactors lowers α-KGDC
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stimulation by Ca2+ [24]. Also, calcium enters the mito-
chondria through a uniporter, a process driven by the nega-
tive potential across the IMM [32]. With respect to this,
cancer cells have been shown to be particularly sensitive to
an arrest of mitochondrial metabolism through the inhib-
ition of Ca2+ transfer into the mitochondria. Indeed, while
normal cells slow down proliferation when Ca2+ import is
inhibited, cancer cells proceed through mitosis and end up
necrotic, a route that may be rescued through dimethyl-α-
KG supplementation [33]. This finding indicates that cancer
cells ought to rely on a functional TCA cycle to sustain suc-
cessful proliferation, and that α-KG may help overcome cal-
cium shortage and sustain a minimal OXPHOS activity, or
may drive adaptive responses to oxidative metabolism
impairment.
pH-mediated regulation of the α-KGDC
A tight link between α-KGDC and OXPHOS is further
exemplified when considering the role of pH in α-KGDC
regulation. It has been widely shown that cytosolic Ca2+
elevation leads to rapid mitochondrial acidification,
boosting oxidative metabolism. A range of pH between
6.6 and 7.4 has been demonstrated to increase α-KGDC
activity [22]. Nonetheless, cytosolic pH is ~7.6 whereas
in the mitochondrial matrix it ranges between 7.5 and
8.2 [34, 35]. The α-KGDC activity would thus be pro-
moted upon environment acidification. In agreement
with this, α-KG concentration in acidotic rat kidneys
significantly decreases due to an increase of α-KGDC ac-
tivity [36], which raises the question of whether changes
in pH affect mitochondrial function in cancers, since
they mostly rely on aerobic glycolysis and undergo a
prominent acidosis [2]. However, cancer cells secrete
lactate/H+ to maintain intracellular pH at physiological
values, leading to the acidification of the extracellular
microenvironment [37]. Noticeably, pH in the mito-
chondria is inherently related to the activity of the ETC
that is driven by the proton motive force and Δψm [18].
Thus, the pH of the mitochondrial matrix would rather
reflect the equilibrium between proton extrusion and
entry into the matrix, mainly driven by OXPHOS activ-
ity [38]. It may be easily argued that a low OXPHOS
activity is associated with a decrease of pH in the mito-
chondrial matrix due to proton accumulation, at least
around the inner membrane. In this respect, the subse-
quent induction of α-KGDC activity and of the subse-
quent NADH generation might help maintaining a
proper chemical gradient by fostering CI proton pump-
ing in the IMS. Hence, beside the adenine nucleotide
phosphorylation state, the NADH/NAD+ ratio and cal-
cium levels, the OXPHOS might exert an additional
control on the α-KGDC through the modulation of pH
in the matrix of mitochondria.
ROS and α-KGDC activity
ROS are by-products of mitochondrial oxidative metab-
olism and their levels are a reliable indicator of ETC
damage [39]. Noteworthy, α-KGDC can both sense and
generate ROS (Fig. 1). An increase in ROS levels may
decrease or completely inhibit α-KGDC function via two
different mechanisms involving the modification of LA.
While a post-translational modification may lead to the
partial and reversible inhibition of the enzyme, the gener-
ation of a thiyl radical on the cofactor precedes its
complete inactivation [40–42]. On the other hand, in re-
sponse to NADH accumulation, stimulated by increased
α-KG levels, the E3 subunit may generate H2O2 [43, 44]
(Fig. 1) at much higher levels than CI [45]. Although
physiological amounts of ROS are essential for cell sur-
vival, their excess fosters cancer initiation and progression
through the induction of genomic instability, gene expres-
sion modifications, and the activation of signaling path-
ways [46, 47]. The aconitase is the most ROS-sensitive
TCA cycle enzyme [48], and its inhibition in cells may
therefore limit NADH production by interrupting the
cycle from pyruvate to α-KG, and thus electron flux
through the respiratory chain, ultimately reducing ROS
in a negative loop. Conversely, cancer cells’ high reliance
on glutamine metabolism may allow the α-KGDC to
fully sustain NADH-linked respiration [49], even upon a
great reduction of aconitase activity. However, unlike the
latter, high ROS levels are required to inhibit the α-KGDC
[42]. In this light, the elevated threshold might play a
prominent role in the progression of tumors with ETC de-
fects. Similarly, prolonged metabolic perturbations such as
NADH and α-KG accumulation may lead to α-KGDC-
dependent oxidative stress, which in turn may profoundly
affect cancer cell redox state and metabolism through a
ROS-mediated self-inactivation of the enzyme [50]. Based
on these characteristics, with the aim of proposing poten-
tial anti-cancer treatment, Stuart and co-workers de-
scribed a member of anti-cancer lipoate derivatives, CPI-
613, which induces an E3-mediated burst of ROS leading
to E2 inactivation in cancer cells [51]. Although CPI-613
is known to be implicated in cell death, whether this is
due to α-KGDC inhibition, ROS overproduction, or to the
reduction of the activity of other lipoate-dependent mito-
chondrial metabolic enzymes remains unclear [51, 52].
The α-KGDC in cancer metabolic reprogramming
Glucose and glutamine are the two primary nutrients
utilized by cancer cells [11]. However, unlike glucose,
which only provides carbon for biosynthesis, glutamine
can provide both carbon and nitrogen for anabolic reac-
tions, thereby conferring substantial additional benefits
[53]. Cancer cells also depend on lipid biosynthesis for
biomass increase [54–56]. A crucial precursor of fatty
acids biosynthesis is the citrate that is canonically
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provided by glucose and glutamine metabolism through
a forward running TCA cycle [10]. Instead, in neoplastic
cells under hypoxic condition or in the presence of ETC
defects, citrate is generated from reductive carboxylation
of glutamine-derived α-KG, by cytosolic and mitochondrial
NADPH-dependent IDH1 and 2, respectively [12, 13]. The
α-KG conversion to isocitrate implies a lower α-KGDC ac-
tivity and the unbalance of the α-KG/citrate ratio, leading
to a TCA cycle functioning in a reverse mode, ultimately
supporting de novo fatty acids synthesis and favoring
tumor growth [13, 56, 57] (Fig. 2). It is worth noting that
the activity of the α-KGDC is reduced via the hypoxia
inducible factor 1 (HIF1)-mediated degradation of a splice
variant of the E1 subunit, whose prevention renders cancer
cells dependent on citrate or exogenous lipids to prolifer-
ate, and impedes tumor growth in vivo [56]. HIF1, the
master regulator of the hypoxic response in malignant can-
cer cells [58], might also contribute to increase the α-KG/
citrate ratio by inhibiting the activity of PDH and therefore
citrate generation [59, 60] (Fig. 2a). These findings high-
light an important role for HIF1 in modulating TCA
metabolites levels and in the rewiring of α-KG fate from
oxidative to reductive metabolism. In line with this, it has
been shown that, in normoxia, constitutive activation of
HIF1 alone is able to promote the reductive carboxylation
of α-KG [12, 57]. Nevertheless, HIF1 is not essential in
Fig. 2 Scheme of the molecular actors driving α-KG reductive carboxylation in mitochondria upon hypoxia (a) and in cancer cells with ETC de-
fects (b). Reductive carboxylation requires the elevation of the α-KG/citrate ratio and reduces α-KG to isocitrate that is subsequently converted to
citrate. This latter is shuttled to the cytosol where it is used for the biosynthesis of lipids. Noteworthy, in both cases (a-b), ROS production by ETC
and α-KGDC may induce the inhibition of aconitase and α-KGDC, thereby preventing citrate and α-KG oxidation, respectively. a Upon hypoxia
(5–0.5% O2 tension), HIF1 can participate to the increase of the α-KG/citrate ratio, by preventing both PDH and α-KGDC activity, in turn limit-
ing citrate production and α-KG oxidation, respectively. (b) In cancer cells with ETC defects, the accumulation of NADH may lead to the inhib-
ition of mitochondrial NADH-dehydrogenases (PDH, IDH, and α-KGDC), thus decreasing citrate production/oxidation and α-KG oxidation.
Further, NADH increase may also promote NADPH-dependent IDH1/2 activity. Finally, it is important to note that NADH accumulation might
also foster reductive carboxylation under low oxygen tension. The TCA metabolic flux is represented by blue arrows ( ), and ( ) indicate
the specific enzyme for each TCA cycle step. Ac-CoA (Acetyl-Coenzyme A; Aco (aconitase); Cit (citrate); Isocit (Isocitrate); Gln (Glutamine);
α-KG (α-ketoglutarate)
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driving the reduction of α-KG since any conditions
leading to a high α-KG to citrate ratio might promote
it, by mass action on the TCA cycle flux [14]. For in-
stance, in hypoxia and in cancer cells with ETC defects,
the decrease of α-KG oxidation may be driven by
changes in the levels of reducing equivalents. In this
scenario, modifications of the mitochondrial redox state
might account for the inhibition of the TCA dehydroge-
nases α-KGDC and PDH and for the promotion of the
NADPH-dependent IDHs [12, 14, 61, 62] (Fig. 2b). Fur-
thermore, ETC defects or hypoxia often lead to increase
in ROS [63], which may contribute to the reduction of
α-KGDC and aconitase activity. In this condition, the
ROS-mediated inhibition of α-KGDC might foster α-KG
accumulation and its diversion towards lipid biosyn-
thesis, while the inactivation of aconitase might con-
tribute to the accumulation and the extrusion of citrate
from mitochondria [64] (Fig. 2).
Silencing OGDH in cancer cells with mitochondrial
defects has been shown to prevent the production of
sufficient levels of NADH, ultimately increasing the
NADP+/NADPH ratio and preventing the NADPH-
dependent IDHs to reduce α-KG [13]. This observation
demonstrates that a minimal activity of α-KGDC is es-
sential for the occurrence of reductive carboxylation and
that this enzyme may operate even in the presence of
respiration defects. Accordingly, HIF1 does not mediate
a complete inhibition of α-KGDC activity, but only up
to approximately 60% [56]. Moreover, accumulation of
α-KG represses HIF1α stabilization and its downstream
pathway by fostering the activity of the metabolic sensor
prolyl hydroxylases (PHDs). This may represent a feed-
back control to keep the enzyme under the stringent
regulation required for metabolic adaptation to hypoxia.
To the same extent, the NADH and ROS-mediated
regulation of α-KGDC activity represents additional
feedback mechanisms that prevent complete enzyme
inactivation. Since the forward and reverse modes of the
TCA cycle are not exclusive, a fine-tuning of α-KGDC
activity is required to balance α-KG fate in both ener-
getic and anabolic pathways, according to oxygen levels
and to ETC status.
In great contrast with impaired respiration, conditions
of nutrient deprivation lead to OXPHOS enhancement
and increase the NAD+/NADH ratio in the matrix,
hence promoting mitochondrial biogenesis, fatty acids
oxidation, and preventing oxidative stress [65, 66]. Sur-
prisingly, a decrease in α-KGDC activity and thereby of
mitochondrial ATP synthesis, due to the accumulation
of α-KG and subsequent inhibition of the ATP synthase,
has been shown to mimic calorie restriction in Caenor-
habditis elegans [67]. This mechanism is proposed to
ensure energetic efficiency in response to nutrient
deprivation [67] and suggests that decreasing α-KGDC
activity is not in contradiction with optimal cellular res-
piration. However, the accumulation of α-KG in starved
animals appears to come from an increase in glutamine
metabolism to sustain anaplerotic gluconeogenesis
from amino acids catabolism and not from a decrease
in α-KGDC activity [68]. Thus, the relevance of this
mechanism has yet to be proven in cancer cells, where
nutrient requirements and metabolic networks are
known to be drastically different from non-malignant
cells. In cancer cells, glutaminolysis exceeds the cellular
requirement for glutamine in the production of amino
acids, nucleotides, and energy [69]. Duràn and co-workers
have shown that α-KG levels are a crucial sign of amino
acids availability status. In this scenario, high cytosolic
levels of α-KG may promote mammalian target of rapa-
mycin 1 (mTORC1) signaling, which in turn blocks au-
tophagy, the housekeeping mechanism to survive nutrient
deprivation stress, and increases anabolism in neoplastic
cells. On the other hand, low levels of α-KG have opposite
effects and correlate with reduced mitochondrial respir-
ation and ATP levels [70, 71]. In this light, it might be
hypothesized that the high α-KG production due to
enhanced glutamine metabolism might be beneficial for
cancer cells by promoting proliferation while inhibiting
autophagy [72]. However, the complex interplay between
glutamine metabolism and the regulation of mTOR and
autophagic processes in cancer cells makes an uncertainty
whether α-KG plays a pivotal role in this respect [73]. In
addition, upon glucose deprivation, treatment with α-KG
derivatives and its reduced form 2-hydroxyglutarate (2-
HG) has revealed the ability to inhibit the ATP synthase,
resulting in mTOR signaling reduction and autophagy
blockage in cancer cells [74]. Overall, these findings
suggest that α-KG levels variation may differently affect
autophagy regulation according to nutrient availability
and compartmentalization of the metabolite (i.e., cyto-
solic versus mitochondrial), whose regulation still war-
rants investigation.
Is α-KG an oncometabolite?
Mutations in fumarate hydratase (FH), succinate de-
hydrogenase (SDH), and IDH1 and IDH2 are associated
to specific human neoplasms that hence accumulate suc-
cinate, fumarate, and (R)-2-HG, respectively, all convey-
ing broad oncogenic signals [75]. Mutations in FH and
SDH follow the classic Knudson “two-hit” model, with
somatic loss of gene function leading to the accumula-
tion of their substrates. In a non-canonic fashion, a sin-
gle allele mutation in IDH1/2 creates a neomorphic
enzyme with increased affinity for α-KG, from which an
excess of the (R)-2-HG metabolite is produced [75, 76].
The prime mechanism of action of these so-called
“oncometabolites” lies within the fact that they are struc-
turally and metabolically similar to α-KG and retain the
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capacity to regulate a family of more than 60 enzymes
involved in fatty acid metabolism, collagen biosynthesis,
nutrient sensing, oxygen sensing, and epigenome editing
[77, 78]. These enzymes are the Fe(II)/α-KG-dependent
dioxygenases, and they include the PHDs introduced
earlier. They are ubiquitously expressed and catalyze hy-
droxylation reactions on several targets. Moreover, they
all use α-KG and O2 as co-substrates and require Fe(II)
as a cofactor to produce succinate and CO2 [79]. Add-
itionally, ascorbate is required to induce the reduction of
Fe(III) to Fe(II), thus restoring enzyme activity [80, 81].
Noticeably, even in the absence of O2, α-KG alone is
sufficient to promote the activity of a subset of Fe(II)/
α-KG-dependent dioxygenases, [82], which are instead
inhibited by succinate and fumarate [83]. (R)-2-HG oc-
cupies the same binding site of α-KG and thereby acts
as a competitive inhibitor [84]. Since the KM of dioxy-
genases for α-KG is close to the metabolite physio-
logical concentration, any condition causing even a
modest variation in the cytosolic levels of α-KG may
profoundly modify dioxygenases-mediated signals.
Understanding α-KG dynamics and their effect on its
downstream targets
A comprehensive identification of enzymes that use α-
KG to carry out their reactions will help to better define
the metabolite role in bridging mitochondrial function
to metabolic reprogramming in cancer cells. In this
frame, PHDs have been extensively studied, in particular
for their role in the response to hypoxia by determining
HIF1α stabilization (Fig. 3). The transcription factor
HIF1 consists of an α- and a β-subunit, which are both
constitutively produced. Under normoxic conditions,
HIF1α is degraded following the hydroxylation of two
specific prolyl residues in its oxygen-dependent degrad-
ation domain (ODDD), operated by three different en-
zymes, namely PDH1, 2, and 3. This in turn recruits an
E3 ubiquitin ligase complex containing the Von Hippel
Lindau protein (pVHL), resulting in HIF1α ubiquityla-
tion and subsequent degradation by the proteasome.
Conversely, in hypoxia, the PHDs low affinity for oxygen
does not allow them to hydroxylate HIF1α, which can-
not be degraded and becomes stabilized. Although the
three PHDs have been reported to be competitively
inhibited by several TCA metabolites and pyruvate
[83, 85–88], the most consistent effects are observed
with fumarate and succinate [88] (Fig. 3). Accordingly,
chronic inhibition of PHDs in both SDH-deficient and
FH-deficient tumors is associated with the stabilization
of HIF1α and activation of downstream hypoxic path-
ways even in normoxia (i.e., pseudohypoxia) [87]. Never-
theless, it is yet unclear whether the pseudohypoxic
response caused by TCA cycle defects is sufficient per se
to promote tumorigenesis or to support tumor progres-
sion [75]. Accumulation of α-KG, on the other hand,
may have an opposite effect and rather lead to the con-
stitutive destabilization of HIF1α. Accordingly, Gottlieb
and his group have shown that the increase in α-KG
alone is sufficient to oppose succinate, fumarate, and
hypoxia-mediated activation of HIF1α. This resulted
in the reversal of enhanced glycolysis and cell death
[82, 89]. Hence, the levels of α-KG, even in hypoxia,
may be sufficient to foster PHD activity and prevent
the hypoxic response. In line with this, our group has
Fig. 3 Schematic representation of the influence of α-KG levels and compartmentalization on PHDs and ATP synthase. PHDs have a dual role in
the context of cell response to resources availability. PHDs control both adaptations to reduced oxygen levels, through HIF1α destabilization, and
to nutrient availability via mTOR promotion. Cytosolic accumulation of α-KG may promote both PHDs and mTOR pathway and may inhibit HIF1
signaling. Conversely, mitochondrial accumulation of α-KG may prevent mTOR activation through the ATP synthase inhibition
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demonstrated that cancer cells with severe mitochon-
drial CI impairment display an increase of α-KG/succin-
ate ratio, likely due to an inhibition of α-KGDC resulting
from an increased NADH/NAD+ ratio. This accumula-
tion is associated to a constitutive destabilization of
HIF1α even in a hypoxic environment (i.e., pseudonor-
moxia), together with a reduction of the tumorigenic
potential in vivo [62, 90–92]. Importantly, both mito-
chondrial impairment and hypoxia can lead to the over-
production of L-(R)-2-HG, which is mostly generated
by the conversion of glutamine-derived α-KG and com-
petes with the latter [12, 61, 93–95]. Thus, dioxy-
genases would respond to the (L)-2-HG/α-KG ratio
rather than to α-KG levels. Unlike (R)-2-HG, the L en-
antiomer does not stem from IDH1 or IDH2 mutations,
but via a promiscuous activity of lactate dehydrogenase
A (LDHA), MDH1 and PHGDH in the cytosol, and via
MDH2 activity in the mitochondria, in a NADH-
dependent manner [93, 96–98]. Hence, changes in the
redox state as NADH accumulation and the subsequent
modification of enzymatic functions associated to im-
paired respiration would foster α-KG conversion into
(L)-2-HG. It has recently been remarked that an essen-
tial role of the respiratory chain is to transfer electrons
from reduced substrate to oxygen, thereby maintaining
an adequate redox state to allow aspartate synthesis
and sustain cancer proliferation [26, 99]. In this con-
text, it is plausible to envision that the α-KG may alter-
natively accept electrons and become reduced to (L)-2-
HG, behaving as a de facto substitute of the ETC to
support cancer growth. Consistently with this, supple-
mentation with α-KG or inhibition of α-KGDC in nor-
moxia causes a slight increase in (L)-2-HG levels,
whereas in hypoxia the increase is far higher [93]. In the
presence of respiration defects, on the other hand, the
subsequent accumulation of α-KG might have different
effects depending on its conversion rate into (L)-2-HG,
as the enantiomer may inactivate PHDs over a certain
threshold. It appears unlikely that the reduction of
OXPHOS alone is sufficient to drive the (L)-2-HG-medi-
ated HIF1 response, since, as shown by our group, a se-
vere CI impairment rather prevents HIF1α stabilization.
Additional factors would thus be required (Fig. 4).
Besides low PHD activity due to the oxygen shortage,
additional mechanisms may be envisioned. For instance,
in physiological situations, the (L)-2-HG dehydrogenase
(L2HGDH) converts (L)-2-HG back to α-KG [100],
whereas in hypoxia L2HGDH expression is decreased by
50% and is therefore important to maintain a high (L)-2-
HG/α-KG ratio (Fig. 4). Furthermore, a low L2HGDH
activity would promote the production of ROS [93] with
consequent HIF1α stabilization [101] (Fig. 4). It is re-
markable that the regulation of L2HGDH expression is
HIF1-independent, thus suggesting a potential upstream
role in the initiation of the hypoxic response. Strikingly
however, a recent study carried out by Burr and co-
workers has shown that disruption of OGDH leads to
HIF1α accumulation in normoxia via a ROS-independent
PHD2-mediated mechanism that relies on (L)-2-HG pro-
duction through both MDH1/2 and LDHA [102]. Hence,
while cell response to hypoxia is mediated by multiple sig-
nals, including O2, reductive equivalents, α-KG, (L)-2-HG
and ROS, the modulation of α-KGDC activity alone may
have a great impact on HIF1α stabilization. To support
this, it was shown that decreasing PHD activity does not
inevitably promote the HIF1-signaling pathway, even in
hypoxia. This seems to depend on a diminished HIF1α
translation, due to a decreased mTOR signaling that
follows O2 and amino acids deprivation, and hence, low
levels of cytosolic α-KG, as PHDs are enhancers of mTOR
activity (Fig. 3) [71]. Both low and high levels of α-KG
may therefore impede the hypoxic response, suggesting
that the maintenance of a certain α-KG amount is essen-
tial for HIF1 activation. In this light, it is possible to
speculate that maintaining α-KGDC activity in an appro-
priate range would not only permit cells to meet meta-
bolic requirements in hypoxia but it would also accurately
control α-KG and (L)-2-HG levels in order to provide cells
with a tailored signal for HIF1 activation.
Besides mTOR, autophagy is also modulated by HIF1
[103], making PHDs and thereby α-KG levels pivotal in
organelles catabolism. Accumulation of α-KG may also
promote mTOR function via ATP synthase inhibition in
the mitochondrion, without involving PHDs [67] (Fig. 3).
Hence, while cytosolic accumulation of α-KG might
prevent autophagy by activating PHDs, the elevation of
its levels in the mitochondria would instead promote it,
via ATP synthase inhibition. Nonetheless, cytosolic
Fe(II)/α-KG-dependent dioxygenases respond to the
ratio between α-KG and its various competitors, whereas
α-KG mediates the inhibition of ATP synthase in a non-
competitive manner [67]. Consequently, the former
mechanism is sensitive to high cytosolic α-KG/2-HG
ratio, generated by an increase in amino acids metabol-
ism or a decrease in OXPHOS. The latter may instead
be triggered by both α-KG and its reduced forms in the
mitochondrial matrix with respect to ATP synthase
abundance, and would serve to optimize cell respiration
according to substrate availability, thereby contributing
to caloric restriction adaptation.
In conclusion, the response to fluctuations of α-KG
levels in cells is multifactorial and remains an open area
of research. The α-KG signaling is likely to be defined by
the metabolite abundance, its oxidation state, and dy-
namics, which are determined by ETC status and oxygen
levels, perhaps among other yet unknown mechanisms.
Based on these considerations, it is plausible to argue
that fluctuations of α-KG levels may be an intrinsic
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characteristic of tumor progression, useful to trigger the
bioenergetic changes in response to selective pressures.
In this light, the role of α-KG remains dual as it may
promote both oncogenic and tumor suppressive func-
tions, paralleling the oncojanus function of mitochon-
drial genes, as we have previously proposed [91].
Impact of α-ketoglutarate on cancer cell epigenetics
Epigenetics alterations at both DNA and histone levels
are increasingly being recognized as modifiers of tumori-
genesis [104]. CpG islands are widely hypermethylated
in many cancer types compared to the corresponding
normal tissue, while the rest of the genome is rather
subject to demethylation. The hypermethylation of CpG
islands has been utilized as a criterion to distinguish dif-
ferent tumor types from non-malignant tissue [105], and
tumors characterized by high levels of DNA methylation
have been classified as having a CpG island methylator
phenotype and are predominantly associated with worse
prognosis, potentially due to a silencing of tumor sup-
pressor genes. In many cases, this phenotype originates
in early phases of tumorigenesis of many tumor types
such as glioblastomas, acute myeloid leukemias, gastric
cancer, and ependymomas [106–111], where drugs tar-
geting the DNA methylation machinery are a promising
strategy.
The large family of α-KG-dependent dioxygenases in-
cludes two classes of enzymes involved in demethylation
and hydroxylation reactions of DNA and histones. The
ten-eleven translocation hydroxylases (TET 1 to 3)
catalyze DNA demethylation, whereas the Jumonji C
domain containing lysine demethylases (KDM 2 to 7) is
the largest family of histone demethylases [112–114].
Both (L)-2-HG and (R)-2-HG are competitive inhibitors of
TETs and KDMs, and are thus important modifiers of the
epigenetic landscape of cancer cells [84, 94, 115, 116]. Ac-
cordingly, accumulation of (L)-2-HG and (R)-2-HG has
been associated to several types of cancers [96, 117–119].
Similarly, recent studies have revealed that together with
2HGs, succinate and fumarate can also induce alterations
in DNA and histones methylation, thus enhancing cancer
formation [84, 120–125]. These findings suggest that
Fig. 4 Mitochondrial signals that shape the HIF1-mediated metabolic and hypoxic adaptation in cancer cells. The hypoxic response may originate both
from HIF1α stabilization, via the decrease in oxygen levels and the increase in the (L)-2-HG/α-KG ratio that lower PHDs activity, and from HIF1 activation,
due to high ROS levels. In the first instance, reduced oxygen levels may inhibit the L2HGDH activity thereby decreasing (L)-2-HG conversion into α-KG,
together with fostering ROS production. Additionally, the elevation of NADH levels in the mitochondria that stems from decreased respiration inhibits
the malate-aspartate shuttle (MAS) and therefore mitochondrial NADH production from cytosolic reductive power. Both mitochondrial and cytosolic
NADH accumulation foster the activity of the NADH-dependent enzymes MDH1/2, PHGDH and LDHA that convert α-KG into (L)-2-HG.
Furthermore, the potential production of ROS by the ETC and α-KGDC might further promote HIF1 activation. Finally, both NADH and HIF1
may inhibit α-KGDC and PDH, further promoting α-KG accumulation, in turn converted into (L)-2-HG or utilized for lipid biosynthesis
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different cytosolic concentrations of α-KG affect the
methylation status of both histones and DNA and thereby
trigger epigenetic changes. Accordingly, Thompson’s
group has demonstrated how maintenance of a proper
α-KG to succinate ratio is fundamental to determine
the identity and the fate of embryonic stem cells (ESC)
[126]. In particular, a high α-KG/succinate ratio pro-
motes the activity of DNA and histone demethylases,
and modifying this ratio is sufficient to regulate multiple
chromatin modifications. Indeed, treatment with α-KG
supports ESC self-renewal, which is known to display
an unusual “open” chromatin structure, associated to
hypertranscription [127]. In this light, high cytosolic
levels of α-KG would promote high energy-consuming
processes, a hypothesis that is supported by the exist-
ence of the PHD-driven mTOR activation mediated by
α-KG, which fosters anabolic processes. Conversely, in
cancer cells facing hypoxia, it is plausible that α-KG con-
version into (L)-2-HG most likely helps in reducing the
energetic demand while promoting HIF1α stabilization
for hypoxic adaptation. Consistent with this, hypoxia
induces a global increase in trimethylation of histone H3
at lysine 9 (H3K9me3) marks, known to repress gene
expression, through the accumulation of (L)-2-HG that
inhibits the activity of the demethylase KDM4C [94].
Furthermore, oxygen shortage has recently been shown
to directly cause DNA hypermethylation by reducing
TET activity in cancer cells, predominantly at the level
of gene promoters [128]. Notwithstanding this, both
TETs and KDMs may stimulate the transcription of spe-
cific HIF1-targeted genes, while being themselves tran-
scriptional targets of HIF1 [125, 128–133], a mechanism
that most likely compensates for their lower enzymatic
activity. Hence, while oncometabolites and low oxygen
availability can promote a closed chromatin state and a
drop in global gene expression through α-KG-dependent
dioxygenases activity, it is plausible that retaining a
minimal activity of these enzymes would induce a spe-
cific genetic response in cells by restraining transcrip-
tion machinery to HIF1-targeted genes.
Similarly, given the role of α-KG as an indicator of
amino acids availability, it is plausible to speculate the
occurrence of an epigenetic remodeling upon glutamine
deprivation, which may be faced by solid cancers. Ac-
cordingly, a recent study has demonstrated that glutam-
ine deficiency is associated to low α-KG levels, which may
in turn determine the inhibition of KDMs in the core re-
gions of the tumor. In this context, the increase in histone
methylation induces cancer cells dedifferentiation and
may cause therapy resistance [134].
The consequence of epigenetics modifications is the
transduction of external stimuli into a transcriptional re-
sponse, thus adjusting cells phenotype without affecting
their genotype [135]. It is most likely that cell bioenergetic
changes driven by external and internal selective pressures
promote an intricate epigenetic remodeling through
α-KG signaling.
Conclusions
A revisited role of mitochondria highlights that they are
not mere bystanders during carcinogenesis. The ever-
changing tumor microenvironment may force cells to
rely on fluctuating levels of oxygen, as well as varying
availability and types of nutrients, whereby optimization
of substrates utilization and a continuous restructuring
of both metabolic and genetic signatures becomes
mandatory for survival. In this review, we have
highlighted a hub role for the TCA cycle enzyme α-
KGDC as a front-line player in the adaptation of cancer
cells to a demanding environment in vivo. This enzyme
may be considered a gatekeeper of the OXPHOS system
and one of the major regulators of mitochondrial metab-
olism. Indeed, α-KGDC responds to OXPHOS activity
fluctuations, controls the mitochondrial redox status
through NADH and ROS levels balance, and directs the
TCA metabolite fluxes towards energetic, anabolic, and
signaling pathways. Changes in α-KGDC activity, and con-
sequently in overall mitochondrial bioenergetics, may im-
pact not only on TCA cycle fluxes but may become
amplified and eventually drive an intricate metabolic and
epigenetic remodeling. Overall, NADH/NAD+ and AMP/
ATP ratio, oxidative stress, membrane potential, and oxy-
gen levels are pivotal players in the translation of the α-
KG signal. In turn, α-KG and its reduced forms may influ-
ence the activity of dioxygenases to shape cells metabolic
and epigenetic landscape according to oxygen and nutri-
ent availability and ETC efficiency. In this light, the α-
KGDC and its substrate appear to be inescapable actors
in cancer cells plasticity. It is remarkable that genetic
and metabolic modifications within a tumor mass are
likely to differ from cell to cell thereby contributing to a
phenotypic heterogeneity, thus accounting for therapy
resistance and disease progression [134, 136]. Several
studies have considered the anti-tumorigenic properties
of α-KG but its mechanisms of action are still not fully
understood. The anti-tumorigenic effect observed upon
in vivo treatment with derivatives of α-KG has been
shown not only to depend on impaired HIF1 signaling
pathway but also to a much greater extent on multiple
unknown side effects of α-KG on tumor growth [94]. In
this frame, it has been reported that α-KG antagonizes
the effect of other oncometabolites, and might therefore
be considered a tumor suppressor metabolite. Neverthe-
less, α-KG supplementation leads to the risk of feeding
oncogenic pathways not only due to its conversion into
(L)-2-HG in respiratory deficient cells but also into suc-
cinate and fumarate, on a long-term treatment [137]. On
the other hand, several human Fe(II)/α-KG-dependent
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dioxygenases have been investigated as possible thera-
peutic targets and might represent an interesting alter-
native strategy to render tumors more sensitive to
radiotherapy and chemotherapy [90]. A complete un-
derstanding of the α-KG-mediated interplay between
metabolic and genetic reprogramming will help us to
disclose a new therapeutic window in which cancer
progression can be restrained. While cancer is defined
as a genetic disease, there is nowadays a growing and
legitimate interest in its metabolic dimension. In par-
ticular, these two aspects are increasingly recognized as
being so interconnected that they are likely to represent
the two edges of the same sword.
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	 	 	 	 	 	 Evaluation	of	the	thesis	of	Renaud	Vatrinet	 
	 	 	 	 	 	 	 Nice,	30th	March,	2017	
	
To	whom	is	concerned,	
The	thesis	of	Mr	Renaud	Vatrinet	concerns	the	“Targeting	Mitochondrial	Respiratory	Complex1:	a	novel	
anticancer	strategy”.	Mr	Varinet	has	endeavored	to	understand	the	involvement	of	the	mitochondrial	complex	1	in	
oncocytic	 tumors	 under	conditions	of	hypoxia.	 Although	 the	 link	 between	Complex	1	and	HIF1	has	already	been	
established	 within	 the	 team,	Mr.	 Vatrinet’s	 main	 goal	 has	 been	 to	 generate	 in	 vivo	 models	 to	 support	 in	 vitro	
observations.	
The	 thesis	 of	 Mr	 Vatrinet	 is	 very	 well	 written	 and	 is	 based	 on	 a	 well	 detailed	 and	 well	 referenced	
Introduction.	The	State-of-the-art	is	well	documented	and	almost	completed,	as	a	more	detailed	paragraph	on	HIF-
2	would	have	been	appropriate.	The	working	hypotheses	are	clear	and	the	Materials	and	Methods	is	complete	and	
will	allow	those	who	will	continue	the	work	to	be	able	to	make	experiments	identical	to	Mr	Varinet.	
The	results	obtained	by	Mr	Vatrinet	are	of	high	quality.	They	are	not	debatable	and	reveal	a	high	scientific	
quality.	 The	 Discussion	 is	 well	 conducted	 and	 of	 valuable	 scientific	 interest.	 Mr	 Vatrinet	 shows	 that	 although	
complex	 1-deficient	cells	 can	 adapt	 their	metabolism	 to	 sustain	 proliferation,	 Complex	 1	 is	 however	 required	 to	
sustain	 cell	 tumorigenic	 properties.	 Notwithstanding	 the	 decline	 in	 xenografts	 growth	 rate,	 long	 term	 in	 vivo	
experiments	have	shown	that	the	 lack	of	Complex	1	did	not	prevent	tumors	training	and	progression,	suggesting	
that	they	have	successfully	met	the	biomass	production	requirements.	However,	when	NDUFS3	was	removed	from	
the	 xenograft,	 it	 was	 found	 that	 this	 	 had	 a	 negative	 effect	 on	 its	 growth.	 In	 addition,	 removing	 NDUFS3	 from	
xenografts	 have	 successfully	 recovered	 one	 key	 oncocytic	 feature	 that	 is	 the	 accumulation	 of	 defective	
mitochondria.	The	most	important	finding	of	this	study	is	that	it	can	be	used	to	treat	benign	oncocytic	phenotype.	
As	said	before,	I	would	have	liked	that	Mr.	Vatrinet	looks	at	the	potential	role	of	HIF2	in	these	tumors	specifically.	
But	maybe	it	will	be	the	subject	of	another	study	later.	
In	summary,	it	is	a	very	good	thesis	that	I	have	greatly	enjoyed	reading,	with	which	I	learned	a	lot	and	that	
I	will	keep	in	my	archives	as	soon	as	I	will	ask	myself	about	Complex	1.	
I	have	only	few	minor	comments	related	to	some	references	that	are	missing	and,	as	I	said	before,	related	
to	a	more	accurate	paragraph	relted	to	HIF2.	
	
Dr	Nathalie	Mazure	
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